Cisgenic plants and methods and compositions related thereto
A novel expression construct with a T-DNA right border sequence identical to cisgenic nucleotides ensures stable gene integration in plants, addressing integration challenges and regulatory issues, thus improving cisgenic vector systems.
Patent Information
- Application Number
- PCT/US2026/027504
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-19
AI Technical Summary
Current cisgenic vector systems face challenges in ensuring stable gene expression, achieving targeted integration, and minimizing off-target effects, while traditional transgenic approaches raise regulatory and public acceptance issues due to the introduction of foreign genetic material.
A novel expression construct design is employed, featuring a T-DNA with a right border sequence identical to three consecutive nucleotides within the cisgenic sequence, facilitating integration of the cisgenic sequence without residual vector sequences, and utilizing Agrobacterium-mediated transformation for precise gene insertion.
This approach enables stable integration of cisgenic nucleotide sequences into plant genomes without unwanted vector sequences, enhancing consumer acceptance and simplifying regulatory pathways.
Smart Images

Figure US2026027504_19112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No: PAT-109797-WO-SEC-1
[0002] CISGENIC PLANTS AND METHODS AND COMPOSITIONS RELATED THERETO FIELD
[0003] The present invention relates to compositions and methods for cisgenic insertion of a nucleotide sequence of interest in a plant.
[0004] RELATED APPLICATIONS
[0005] This application claims priority to US Provisional Patent Application No. 63 / 804297, filed May 12, 2025, the contents of which are incorporated by reference herein in their entirety.
[0006] STATEMENT REGARDING ELECTRONIC SUBMISSION OF A SEQUENCE LISTING A Sequence Listing in XML format, submitted under 37 C.F.R. § 1.831-1.835, entitled PAT-109797-PCT.xml, generated on May 8, 2026, and approximately 77 kilobytes in size, has been filed via EFS-Web and is provided in lieu of a paper copy. This Sequence Listing is hereby incorporated by reference into the specification in its entirety.
[0007] BACKGROUND
[0008] In the field of genetic engineering, the development of vectors for the introduction of specific genes into host organisms is an important area of research. Traditional transgenic approaches often involve the incorporation of foreign DNA from different species, which can raise regulatory and public acceptance challenges. In contrast, cisgenic vectors aim to utilize genes from the same species or a closely related one, maintaining the natural genetic makeup of the organism.
[0009] Cisgenic technology offers several advantages, including improved consumer acceptance and potentially simplified regulatory pathways. This approach is particularly relevant in agriculture, where the introduction of beneficial traits such as disease resistance, drought tolerance, or enhanced nutritional content can be achieved without introducing undesired foreign genetic material.
[0010] Despite these advantages, the development of effective cisgenic vectors presents several challenges. These include ensuring stable gene expression, achieving targeted integration, and minimizing off-target effects. In addition, the incorporation of undesired sequences from theAttorney Docket No: PAT-109797-WO-SEC-1
[0011] vector have to be minimized. Current methods often rely on traditional vector systems, which may not be optimized for cisgenic applications.
[0012] SUMMARY
[0013] Provided herein are methods and compositions for the use of a novel expression construct design for plant transformation, the resulting transformed plants, and the associated transformation method. Various embodiments describe an expression construct comprising at least one T-DNA with a right border sequence, a cisgenic nucleotide sequence of interest, and a left border sequence. In various embodiments, the right border includes a 3' portion that is identical to three (or at least three) consecutive nucleotides within the cisgenic sequence such that, when transformed into a plant cell, this design facilitates the integration of the cisgenic sequence and the formation of a 5' cisgenic junction in which no residual transformation vector sequences are integrated into the genome of the transformed plant.
[0014] Embodiments also describe methods of transforming a plant cell with a cisgenic nucleotide sequence of interest by transforming a plant cell with an expression construct comprising at least one T-DNA with a right border sequence, a cisgenic nucleotide sequence of interest, and a left border sequence, wherein the right border includes a 3' portion that is identical to three, or at least three, consecutive nucleotides within the cisgenic sequence, and then selecting for transformants having the cisgenic sequence integrated into the genome of the transformed plant cell via the formation of a 5' cisgenic junction comprising no residual transformation vector sequence.
[0015] Embodiments further describe cisgenic plants or plant cells comprising a cisgenic nucleotide sequence of interest inserted into a non-native locus of the genome via transformation of the plant cell with an expression construct comprising at least one T-DNA with a right border sequence, the cisgenic nucleotide sequence of interest, and a left border sequence, wherein the right border includes a 3' portion that is identical to three, or at least three, consecutive nucleotides within the cisgenic sequence.
[0016] Various limitations associated with using conventional breeding or conventional transformation vectors for introgressing a genomic region from a source plant into a recipient plant of the same species, or a sexually compatible species, can be overcome using the methods and compositions described herein.Attorney Docket No: PAT-109797-WO-SEC-1
[0017] The foregoing and other objects and aspects of the present invention are explained in detail in the drawings and specification set forth below.
[0018] BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1A-C depicts the construction and design of a novel cisgenic expression construct in accordance with the present disclosure.
[0020] Figure 2 (from top to bottom) depicts an example sequence of a right border of a T-DNA used for transformation of a gene of interest, an example native sequence of a cisgene of interest to be inserted into the genome of a plant cell, an example 5' cisgenic junction sequence in a T-DNA vector / plasmid resulting from the cisgenic expression construct design of the present disclosure, and an example junction sequence resulting from integration of the cisgenic expression cassette into the genome of a plant cell following T-DNA transformation.
[0021] Figures 3A-G depicts an example method of generating a cisgenic plant cell comprising a cisgenic nucleotide sequence of interest integrated into the genome of the plant cell without the insertion of any undesired vector sequences. The method includes transforming a plant cell with a T-DNA vector comprising an expression construct comprising at least one T-DNA with a right border sequence, a cisgenic nucleotide sequence of interest, and a left border sequence, wherein the right border includes a 3' portion that is identical to three consecutive nucleotides within the cisgenic sequence. The method comprises the steps of vector design (A), Agrobacterium mediated transformation (B-C), countersei ection (D), and selection (E-G).
[0022] Figure 4 represents in planta efficacy of cisgenic events and selection of TO events with minimal acceptable efficacy, and the corresponding T1 homozygous efficacy. 06KG transformation line was used as a wild type control. Black dashed line indicates the minimal threshold for desired phenotype. Events with ratings smaller or lower than the dashed line are selected for maturity. The mean value of samples is represented by a white circle.
[0023] BRIEF DESCRIPTION OF THE SEQUENCE LISTING SEQ ID NO: 1 is an example left border sequence of nopaline synthase.
[0024] SEQ ID NO: 2 is an example left border sequence of nopaline synthase.
[0025] SEQ ID NO: 3 is an example left border sequence of octopine synthase.
[0026] SEQ ID NO: 4 is an example right border sequence of nopaline synthase.Attorney Docket No: PAT-109797-WO-SEC-1
[0027] SEQ ID NO: 5 is an example right border sequence of nopaline synthase.
[0028] SEQ ID NO: 6 is an example right border sequence of octopine synthase.
[0029] SEQ ID NO: 7 is a cisgenic nucleotide sequence of interest encoding a resistance protein RG21.
[0030] SEQ ID NO: 8 is a cisgenic nucleotide sequence of interest encoding a resistance protein RG33
[0031] SEQ ID NO: 9 is a cisgenic nucleotide sequence of interest encoding a resistance protein RG31.
[0032] SEQ ID NO: 10 is a cisgenic nucleotide sequence of interest encoding a resistance protein RG35.
[0033] SEQ ID NO: 11 is the coding sequence for a codon optimized counterselection marker gene bamase.
[0034] SEQ ID NO: 12 is the sequence for the promoter from Peanut Chlorotic Streak Caulimovirus (prPCISV).
[0035] SEQ ID NO: 13 is the sequence for a potato Solarium tuberosum) intron iPots.
[0036] SEQ ID NO: 14 is the sequence for the Agrobacterium Nopaline synthase terminator tNOS.
[0037] SEQ ID NO: 15 is the coding sequence for a codon optimized selection marker gene ALS encoding an Acetolactate synthase double mutant (P191A, W568L) from Nicotiana tabacum.
[0038] SEQ ID NO: 16 is the sequence for a soybean translation elongation factor EF-1 alpha promoter prGmEF.
[0039] SEQ ID NO: 17 is the sequence for the soybean EPSPS gene terminator tGmEPSPS.
[0040] DETAILED DESCRIPTION
[0041] This description is not intended to be a detailed catalog of all the different ways in which the disclosed methods and compositions may be implemented, or all the features that may be included. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Thus, the disclosure contemplates that in some embodiments any feature or combination of features set forth herein can be excluded or omitted. In addition, numerous variations and additions to the various embodiments suggested herein will be apparentAttorney Docket No: PAT-109797-WO-SEC-1
[0042] to those skilled in the art in light of the instant disclosure. Hence, the following descriptions are intended to illustrate some particular embodiments and not to exhaustively specify all permutations, combinations, and variations thereof.
[0043] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the presently disclosed subject matter belongs. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds ), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
[0044] Although the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate understanding of the presently disclosed subject matter.
[0045] Nucleotide sequences provided herein are presented in the 5’ to 3’ direction, from left to right and are presented using the standard code for representing nucleotide bases as set forth in 37 CFR §§1.821 - 1.825 and §§1.831 - 1.835 and the World Intellectual Property Organization (WIPO) Standard ST.25, for example: adenine (A), cytosine (C), thymine (T), and guanine (G).
[0046] Amino acids are likewise indicated using the WIPO Standard ST.25, for example: alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gin; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (He; 1), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Vai; V).
[0047] Unless the context indicates otherwise, it is specifically intended that the various features described herein can be used in any combination. Moreover, in some embodiments, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a composition comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.
[0048] For clarity, certain terms used in the specification are defined and presented as follows:Attorney Docket No: PAT-109797-WO-SEC-1
[0049] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a plant" is a reference to one or more plants and includes equivalents thereof known to those skilled in the art, and so forth.
[0050] As used herein, the term "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative, “or.”
[0051] The term "about" is used herein to mean approximately, roughly, around, or in the region of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20 percent, preferably 10 percent up or down (higher or lower). With regard to a temperature, the term “about” means ± 1 °C, preferably ± 0.5°C. Where the term “about” is used in the context of this disclosure (e.g., in combinations with temperature or molecular weight values) the exact value (i.e., without “about”) is preferred.
[0052] As used herein, the term "amplified" means the construction of multiple copies of a nucleic acid molecule or multiple copies complementary to the nucleic acid molecule using at least one of the nucleic acid molecules as a template. Amplification systems include the polymerase chain reaction (PCR) system, ligase chain reaction (LCR) system, nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario), Q- Beta Replicase systems, transcription-based amplification system (TAS), and strand displacement amplification (SDA). See, e.g., Diagnostic Molecular Microbiology: Principles and Applications, PERSING et al., Ed., American Society for Microbiology, Washington, D.C. (1993). The product of amplification is termed an “amplicon.”
[0053] “Backbone nucleic acids” or “backbone sequences” refer to nucleic acids or molecules derived from plasmids or vectors (such as the binary vectors described herein) which are not adjacent to a cisgene of interest in its natural environment. These backbone sequences (also referred to herein as “foreign DNA”) include nucleic acids such as self-replicating nucleic acids, viruses, plasmids, and other vectors or nucleic acids used to maintain or manipulate a cisgenic nucleic acid insert of interest. Such backbone sequences do not include the cisgenic nucleic acid insert or cisgenic expression cassette.Attorney Docket No: PAT-109797-WO-SEC-1
[0054] As used herein, “cisgenesis” involves the insertion, optionally into a genome (e g., a plant genome), of one or more genes of the same or a related species, or from a sexually compatible donor. The introduction of specific alleles / genes present in a gene pool via cisgenesis accelerates the breeding of species with long reproduction cycles with no linkage drag.
[0055] As used herein a “cisgenic construct” or “cisgenic expression cassette” is a nucleic acid sequence present in a recombinant recipient cell, and optionally integrated into the recipient cell's genome, wherein the recombinant nucleic acid sequence comprises one or more regulatory element(s) operably linked to a nucleic acid sequence for a gene of interest, wherein the regulatory element and gene of interest are both native (i.e., unmodified) with respect to one another and are derived from the same plant species as the recipient plant cell or from a related species, or a sexually compatible donor of the recipient plant cell. In embodiments, the cisgenic construct comprises a contiguous linear span of genomic DNA, such as a chromosomal interval, that resides in the source plant’s genome on a single chromosome and / or at a single locus. The genetic elements including the gene of interest (herein also referred to as the “cisgene”) and its associated regulatory elements that are derived from the chromosomal interval and are thus physically and genetically linked to the cisgene. In particular embodiments, the cisgene and its regulatory elements are operably linked in the native cell at a genomic location different from the genomic location where they are integrated as the cisgenic construct. The cisgenic construct can be introduced into the genome of the plant / plant cell or recipient plant / plant cell by any method including, for example, transformation of the cisgenic construct or via a gene edit.
[0056] In particular embodiments, where Agrobacterium mediated transformation is used for introducing the cisgenic construct into a plant’s genome, the cisgenic construct may be included within an expression cassette for expression of the cisgenic nucleotide sequence of interest. The expression cassette may be included within a T-DNA vector. For example, the expression cassette may comprise at least one T-DNA having, arranged contiguously, and in the following order, a modified T-DNA right border sequence, the cisgenic construct, and a modified T-DNA left border sequence. Furthermore, the modified T-DNA right border sequence may be modified to comprise a contiguous 5' portion and 3' portion, wherein the 3' portion of the right border has at least three consecutive nucleotides (e.g., three, four, five or more nucleotides) that are identical to the same number of consecutive nucleotides, such as three consecutive nucleotides, located within the cisgenic nucleotide sequence of interest. This positioning enables the nickingAttorney Docket No: PAT-109797-WO-SEC-1
[0057] machinery of Agrobacterium to recognize the modified T-DNA right border sequence, create a nick in the vector at that location, and pilot the single-stranded T-DNA into the recipient plant cell, thereby incorporating the cisgenic construct into the genome of the recipient plant cell. In this way, the three or at least three consecutive nucleotides are shared between the right border sequence and the cisgenic sequence such that in the event of any potential truncation downstream of the right border during transformation and subsequent integration of the cisgenic nucleotide sequence of interest into the plant genome, a plant cell can be generated without incorporating any non-native or foreign sequence from the T-DNA vector into the plant genome at a 5’ cisgenic junction.
[0058] In further particular embodiments, the modified T-DNA left border sequence may be modified to comprise a contiguous 5' portion and 3' portion, wherein the 5' portion of the right border has at least three consecutive nucleotides (e.g., three, four, five or more nucleotides) that are identical to the same number of consecutive nucleotides, such as three consecutive nucleotides, located within the cisgenic nucleotide sequence of interest. This positioning enables the nicking machinery of Agrobacterium to recognize the T-DNA left border sequence, and in the event of any potential truncation upstream of the left border during transformation and subsequent integration of the cisgenic nucleotide sequence of interest into the plant genome, a plant cell can be generated without incorporating any non-native or foreign sequence from the T-DNA vector into the plant genome at a 3’ cisgenic junction.
[0059] As used herein, “cisgenic plant” comprises a recipient plant having a genomic insertion and / or genomic modification, wherein the genomic insertion and / or genomic modification comprises one or more unmodified (i.e., native) gene sequences that are derived from the same plant species as the recipient plant or from a sexually compatible donor of the recipient plant. In various embodiments, the cisgene is transferred along with its natural promoter and terminator sequences, ensuring that the gene is expressed similarly to how it would be in its native context.
[0060] In various embodiments, additionally one or more regulatory elements such as introns, untranslated region (UTR) sequences (including 5 -UTR and 3 -UTR sequences), and / or other non-coding sequences are also transferred along with the cisgene (that is, cisgenic nucleotide sequence of interest) and the native promoter and terminator sequences. Thus, the cisgenic plant is a modified or non-natural plant having a cisgenic construct comprising a native and unmodified gene of interest and associated regulatory element(s) derived from a plant speciesAttorney Docket No: PAT-109797-WO-SEC-1
[0061] inserted into the genome of a plant cell of the same species, or from a sexually compatible donor of the recipient plant cell, inserted into a non-native locus of the genome (such as on a different chromosome than the chromosome of the native locus from which the gene of interest is derived, or at a different position of the same chromosome). In this way, the genotype and phenotype of a cisgenic plant is altered from the native plant using the selected plant’s own nucleic acid or using nucleic acid from a plant that is sexually compatible with the selected plant.
[0062] A "coding sequence" is a nucleic acid sequence that is transcribed into RNA such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA. In some aspects, the RNA is then translated in an organism, such as a plant, to produce a protein. In other aspects, the RNA is not translated to produce a protein but functions as an RNA molecule to modulate expression of a protein.
[0063] The terms "complementary" or "complementarity" (and similar terms), as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A." Complementarity between two single-stranded molecules may be partial, in which only some of the nucleotides bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between the molecules. As used herein, the term “substantially complementary” (and similar terms) means that two nucleic acid sequences are at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more complementary. Alternatively, the term “substantially complementary” (and similar terms) can mean that two nucleic acid sequences can hybridize together under high stringency conditions (as described herein).
[0064] The terms “comprises” or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, or groups thereof.
[0065] As used herein, the transitional phrase “consisting essentially of (and grammatical variants) means that the scope of a claim is to be interpreted to encompass the specified materials or steps recited in the claim” and those that do not materially alter the basic and novelAttorney Docket No: PAT-109797-WO-SEC-1
[0066] character! stic(s)” of the claimed invention. Thus, the term “consisting essentially of when used in a claim of this invention is not intended to be interpreted to be equivalent to “comprising.” As used herein, the terms “disease tolerance” or “disease resistance” refers to a plant’s ability to endure and / or thrive despite being infected with a corresponding disease. Thus “disease tolerance” or “disease resistance” means a statistically significant increase in disease tolerance and / or a statistically significant decrease, or the absence, in one or more disease symptoms of a plant caused by a plant pathogen, when compared to an appropriate control plant. In some embodiments, an increase in disease tolerance or resistance can be (1) measured by a plant’s ability to endure and / or thrive despite being infected with a respective disease; (2) measured by the infected disease resistant plant yielding as well as (or nearly as well) as an uninfected plant; or (3) measured by a delay or the prevention of proliferation of a pathogen (e.g., fungi), including a delay or the prevention in disease related symptoms.
[0067] In particular embodiments, a cisgenic plant comprises a cisgenic nucleotide sequence of interest that, upon transformation into the plant, confers the transformed plant (e.g., a transformed soybean plant or plant cell) with enhanced disease or pathogen resistance. As used herein, “enhanced pathogen resistance”, “enhanced disease resistance”, “increased resistance to a pathogen,” or “confers pathogen resistance” refers to an improvement, enhancement, or increase in a cisgenic plant’s ability to endure and / or thrive despite being infected with a pathogen or disease (e.g., Asian soybean rust) as compared to a control plant (not comprising the cisgenic nucleotide sequence of interest). Enhanced disease resistance includes a reduction in the symptoms indicative of infection for a disease such as Asian soybean rust (“ASR”), soybean cyst nematode, Phytophthora, root knot nematode, bacterial diseases, viral diseases, etc. An enhanced plant pathogen resistance may comprise any statistically significant increase in resistance to the plant pathogen, including, for example, an increase of at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or higher. Conferring or enhancing or increasing resistance may include a reduction (partial reduction or complete reduction) in symptoms or phenotypic characteristics associated with susceptibility to the pathogen and / or an increase in phenotypic characteristics associated with resistance to the pathogen. In example embodiments, conferring or increasing of resistance to Asian Soy Rust can include a statistically significant reduction in the number, size, and / or density of lesions, change in the color of lesions (such as from a tan coloration to a reddish-brown coloration), reduction in number and density of pustule formation,Attorney Docket No: PAT-109797-WO-SEC-1
[0068] reduction in sporulation, reduction in defoliation, a reduction in yield loss, or any combination thereof. In further embodiments, enhanced pathogen resistance can include a statistically significant reduction in the number, size, and / or density of cysts. Further, enhanced pathogen resistance can include the prevention or delay of proliferation of a pathogen (e.g., fungus, nematode, or bacteria) in the cisgenic plant.
[0069] A "control" or "control plant" or "control plant cell" provides a reference point for measuring changes in phenotype of the cisgenic plant or plant cell. A control plant or plant cell may comprise, for example: (a) a wild-type plant or cell, i.e., of the same genotype as the starting material for the cisgenic transformation which resulted in the cisgenic plant or cell; (b) a plant or plant cell of the same genotype as the starting material but which has been transformed with a null construct (i.e., with a construct which has no known effect on the trait of interest, such as a construct comprising only a marker gene but not the cisgene); (c) a plant or plant cell which is a non-transformed segregant among progeny of a subject plant or plant cell; (d) a plant or plant cell genetically identical to the subject plant or plant cell but which is not exposed to conditions or stimuli that would induce expression of the gene of interest; or (e) the subject plant or plant cell itself, under conditions in which the cisgene of interest is not expressed. "Exon" refers to a section of DNA which carries the coding sequence for a protein or part of it. Exons are separated by intervening, non-coding sequences (introns).
[0070] "Expression cassette" as used herein means a nucleic acid sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence.
[0071] An expression cassette also can optionally include a transcriptional and / or translational termination region (i.e., termination region) that is functional in plants. In embodiments, the termination region and transcriptional initiation region are native to each other, native to the operably linked nucleotide sequence of interest, and native to the plant host.
[0072] In particular embodiments, an expression cassette may be included within a T-DNA vector and may comprise at least one T-DNA for introgression of a cisgenic nucleotide sequence of interest into the genome of a plant cell. In one example embodiment, the expression cassette comprises at least one T-DNA having in the following order, a heterologous right borderAttorney Docket No: PAT-109797-WO-SEC-1
[0073] sequence, a cisgenic nucleotide sequence of interest and a heterologous left border sequence; wherein the heterologous right border comprises a contiguous 5’ portion and 3’ portion, wherein the 3’ portion of the right border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest, and wherein transformation of a plant cell with said expression construct results in at least one plant cell having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming a 5’ cisgenic junction.
[0074] In example embodiments, the expression cassette further comprises a second T-DNA comprising a second nucleotide sequence of interest, such as a selectable marker gene flanked by right and left border sequences. The second nucleotide sequence of interest may be operably coupled to a heterologous regulatory element, such as a heterologous plant active promoter, terminator, introns and / or UTRs for driving the expression of the sequence upon introgression of the second nucleotide sequence of interest into the genome of a plant cell. Expression of the selectable marker gene provides a selective advantage to plant cells transformed with the expression cassette when grown in a selective growth condition, allowing for screening and selection of cells comprising the selectable marker gene integrated into the plant cell genome.
[0075] In example embodiments, the expression cassette further comprises a third nucleotide sequence of interest, such as a counterselection marker gene located in a spacer region between the first and the second T-DNA. The third nucleotide sequence of interest may be operably coupled to heterologous regulatory element, such as a heterologous plant active promoter, terminator, introns and / or UTRs for driving the expression of the sequence upon introgression of the third nucleotide sequence of interest into the genome of a plant cell. Expression of the counterselection marker gene provides a selective disadvantage to plant cells transformed with the expression cassette when grown in a selective growth condition, allowing for screening and removal of cells comprising the counterselection marker gene integrated into the plant cell genome. It will be appreciated that in other embodiments, such as where the cisgenic nucleotide sequence of interest confers a selectable trait and can itself be used as a selectable marker, the expression construct may not comprise the second T-DNA comprising the selectable marker and / or the counterselection marker in the spacer region. In further embodiments, the cisgenic nucleotide sequence of interest can be used as a selectable marker, in addition to the selectable marker on the second T-DNA and / or the counterselection marker in the spacer regionAttorney Docket No: PAT-109797-WO-SEC-1
[0076] The term "expression" when used with reference to a polynucleotide, such as a gene, open reading frame (ORF) or portion thereof, refers to the process of converting genetic information encoded in a gene into RNA (e.g., mRNA, rRNA, tRNA, or snRNA) through "transcription" of the gene (i.e., via the enzymatic action of an RNA polymerase), and into protein where applicable (e.g. if a gene encodes a protein), through "translation" of mRNA. Gene expression can be regulated at many stages in the process. In some embodiments, “expression” refers to the transcription and stable accumulation of sense (mRNA) or functional RNA. In some embodiments, “expression” refers to the production of protein.
[0077] A "gene" is a defined region that is located within a genome and comprises a coding nucleic acid sequence and typically also comprises other, primarily regulatory, nucleic acids responsible for the control of the expression, i.e., the transcription and translation, of the coding portion. A gene may also comprise other 5' and 3' untranslated sequences and termination sequences. Further elements that may be present are, for example, introns. A “cisgene” as used herein refers to a gene where the coding nucleic acid sequence and any associated regulatory elements have not been modified and have remained essentially unaltered.
[0078] "Gene of interest" or “cisgene of interest” refers to any nucleic acid molecule which, when expressed in a plant, confers upon the plant a desired trait such as virus resistance, insect resistance, disease resistance, or resistance to other pests, abiotic stress tolerance, modified fatty acid metabolism, modified carbohydrate metabolism, improved nutritional value, improved performance in an industrial process or altered reproductive capability. The "gene of interest" may also be one that is cisgenically transferred in plants for the production of commercially valuable enzymes or metabolites in the plant.
[0079] A "heterologous" nucleic acid sequence or nucleic acid molecule is a nucleic acid sequence that originates from a foreign species; or, if from the same species, is substantially modified from its native form in composition and / or genomic locus by deliberate human intervention. A heterologous nucleic acid sequence or nucleic acid molecule may comprise a chimeric sequence such as a chimeric expression cassette, where the promoter and the coding region are derived from multiple source organisms. In still other examples of a chimeric sequence, one or more native introns of a gene of interest may be removed and / or replaced with introns that originate from a foreign species. The promoter sequence may be a constitutive promoter sequence, a tissue-specific promoter sequence, a chemically-inducible promoterAttorney Docket No: PAT-109797-WO-SEC-1
[0080] sequence, a wound-inducible promoter sequence, a stress-inducible promoter sequence, or a developmental stage-specific promoter sequence.
[0081] A "homologous" nucleic acid sequence is a nucleic acid sequence naturally associated with a host cell into which it is introduced.
[0082] The term “identity” or “identical” or "substantially identical," in the context of two nucleic acid or amino acid sequences, refers to two or more sequences or subsequences that have at least 60%, preferably at least 80%, more preferably 90%, even more preferably 95%, and most preferably at least 99% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the substantial identity exists over a region of the sequences that is at least about 50 residues or bases in length, more preferably over a region of at least about 100 residues or bases, and most preferably the sequences are substantially identical over at least about 150 residues or bases. In an especially preferred embodiment, the sequences are substantially identical over the entire length of the coding regions. Furthermore, substantially identical nucleic acid or amino acid sequences perform substantially the same function.
[0083] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
[0084] Optimal alignment of sequences for comparison can be conducted by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48: 443 (1970).
[0085] "Stringent hybridization conditions" and "stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments such as Southern and Northern hybridizations are sequence dependent and are different under different environmental parameters. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes part I chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays" Elsevier, New York. Generally, highly stringent hybridization and wash conditions are selected to be about 5°C lowerAttorney Docket No: PAT-109797-WO-SEC-1
[0086] than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Typically, under "stringent conditions" a probe will hybridize to its target subsequence, but not to other sequences. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the Tmfor a particular probe. An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formamide with 1 mg of heparin at 42°C, with the hybridization being carried out overnight. An example of highly stringent wash conditions is 0.15M NaCl at 72°C for about 15 minutes. An example of stringent wash conditions is a 0.2* SSC wash at 65°C for 15 minutes (see, Sambrook, infra, for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency wash for a duplex of, e.g., more than 100 nucleotides, is lx SSC at 45°C for 15 minutes. An example low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4-6x SSC at 40°C for 15 minutes. For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is typically at least about 30°C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the proteins that they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.
[0087] The following are examples of sets of hybridization / wash conditions that may be used to clone homologous nucleotide sequences that are substantially identical to reference nucleotide sequences of the present disclosure: a reference nucleotide sequence preferably hybridizes to the reference nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPCri, 1 mM EDTA at 50°C with washing in 2x SSC, 0.1% SDS at 50°C, more desirably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPCri, 1 mM EDTA at 50°C with washing in lx SSC, 0.1% SDS at 50°C, more desirably still in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPCri, 1 mM EDTA at 50°CAttorney Docket No: PAT-109797-WO-SEC-1
[0088] with washing in 0.5cSSC, 0.1% SDS at 50°C, preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPCri, 1 mM EDTA at 50°C with washing in 0.1cSSC, 0.1% SDS at 50°C, more preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPC, 1 mM EDTA at 50°C with washing in 0.1% SSC, 0.1% SDS at 65°C.
[0089] A further indication that two nucleic acid sequences or proteins are substantially identical is that the protein encoded by the first nucleic acid is immunologically cross reactive with, or specifically binds to, the protein encoded by the second nucleic acid. Thus, a protein is typically substantially identical to a second protein, for example, where the two proteins differ only by conservative substitutions.
[0090] As used herein, “intragenic plant” or “intragenesis” refers to a recipient plant having a genomic insertion and / or genomic modification, wherein the genomic insertion and / or genomic modification comprises a combination of one or more unmodified (i.e., native) gene sequences that are derived from the same plant species as the recipient plant, but are combined in a manner that does not exist in the native plant species. In this context, the inserted DNA can be a new combination of native DNA fragments (e.g., combinations of genes with different promoters and / or regulatory elements that independently exist in the native species, but not in the same configuration). For the purposes of the present disclosure, the term “cisgenesis” is used to refer to both cisgenic or intragenic configurations unless otherwise specified herein or would be clear to the skilled artisan that a distinction is intended. As non-limiting examples, intragenesis or cisgenesis may include the introduction of a polynucleotide sequence that is derived from a maize species into the genome of a maize plant, or the introduction of a polynucleotide sequence that is derived from a Glycine max species into the genome of a Glycine max (soybean) plant, or the introduction a polynucleotide sequence that is derived from a Glycine tomentella species into the genome of a Glycine max (soybean) plant.'Tntron" refers to an intervening section of DNA which occurs almost exclusively within a eukaryotic gene, but which is not translated to amino acid sequences in the gene product. The introns are removed from the pre-mature mRNA through a process called splicing, which leaves the exons untouched, to form an mRNA.
[0091] The term "isolated" nucleic acid molecule, polynucleotide or protein is a nucleic acid molecule, polynucleotide or protein that no longer exists in its natural environment. An isolated nucleic acid molecule, polynucleotide or protein of the disclosure may exist in a purified form or may exist in a recombinant host such as in a cisgenic plant. Therefore, a claim to an “isolated”Attorney Docket No: PAT-109797-WO-SEC-1
[0092] nucleic acid molecule, as enumerated herein, encompasses a nucleic acid molecule that is comprised within a cisgenic plant genome.
[0093] A “native” or “wild type” nucleic acid, nucleotide sequence, polypeptide or amino acid sequence refers to a naturally occurring, native, or endogenous nucleic acid, nucleotide sequence, polypeptide or amino acid sequence. Thus, for example, a “wild type mRNA” is an mRNA that is naturally occurring in, or endogenous or native to, the organism. As used herein, the term “endogenous” refers to materials originating from within an organism or cell. “Exogenous” refers to materials originating from outside of an organism or cell.
[0094] A "nucleic acid molecule" or "nucleic acid sequence" is a segment of single- or doublestranded DNA or RNA that can be isolated from any source. In the context of the disclosure, the nucleic acid molecule is typically a segment of DNA. In some embodiments, the nucleic acid molecules of the disclosure are isolated nucleic acid molecules.
[0095] "Operably linked" refers to the association of polynucleotides on a single nucleic acid fragment so that the function of one affects the function of the other. For example, a promoter is operably linked with a coding polynucleotide or functional RNA when it is capable of affecting the expression of that coding polynucleotide or functional RNA (i.e., that the coding polynucleotide or functional RNA is under the transcriptional control of the promoter). Coding polynucleotides in sense or antisense orientation can be operably linked to regulatory polynucleotides.
[0096] The terms "protein," "peptide" and "polypeptide" are used interchangeably herein.
[0097] A "plant" is any plant at any stage of development, particularly a seed plant.
[0098] A "plant cell" is a structural and physiological unit of a plant, comprising a protoplast and a cell wall. The plant cell may be in the form of an isolated single cell or a cultured cell, or as a part of a higher organized unit such as, for example, plant tissue, a plant organ, or a whole plant.
[0099] "Plant cell culture" means cultures of plant units such as, for example, protoplasts, cell culture cells, cells in plant tissues, pollen, pollen tubes, ovules, embryo sacs, zygotes and embryos at various stages of development.
[0100] "Plant material" refers to leaves, stems, roots, flowers or flower parts, fruits, pollen, egg cells, zygotes, seeds, cuttings, cell or tissue cultures, or any other part or product of a plant.
[0101] A "plant organ" is a distinct and visibly structured and differentiated part of a plant such as a root, stem, leaf, flower bud, or embryo.Attorney Docket No: PAT-109797-WO-SEC-1
[0102] "Plant tissue" as used herein means a group of plant cells organized into a structural and functional unit. Any tissue of a plant in planta or in culture is included. This term includes, but is not limited to, whole plants, plant organs, plant seeds, tissue culture and any groups of plant cells organized into structural and / or functional units. The use of this term in conjunction with, or in the absence of, any specific type of plant tissue as listed above or otherwise embraced by this definition is not intended to be exclusive of any other type of plant tissue. For example, the “tapetum” is a tissue within the sporangium, especially the anther, of corn plants that provides nutrition for growing spores.
[0103] “Polyadenylation signal” or “polyA signal” refers to a nucleic acid sequence located 3' to a coding region that causes the addition of adenylate nucleotides to the 3' end of the mRNA transcribed from the coding region.
[0104] “Polymerase chain reaction (PCR)” refers to a DNA amplification method that uses an enzymatic technique to create multiple copies of one sequence of nucleic acid (amplicon).
[0105] Copies of a DNA molecule are prepared by shuttling a DNA polymerase between two amplimers. The basis of this amplification method is multiple cycles of temperature changes to denature, then re-anneal amplimers (DNA primer molecules), followed by extension to synthesize new DNA strands in the region located between the flanking amplimers. Nucleic-acid amplification can be accomplished by any of the various nucleic-acid amplification methods known in the art, including the polymerase chain reaction (PCR). A variety of amplification methods are known in the art and are described, inter alia, in U.S. Pat. Nos. 4,683,195 and 4,683,202 and in PCR Protocols: A Guide to Methods and Applications, ed. Innis et al., Academic Press, San Diego, 1990. PCR amplification methods have been developed to amplify up to 22 kb of genomic DNA and up to 42 kb of bacteriophage DNA (Cheng et al., Proc. Natl. Acad. Sci. USA 91:5695-5699, 1994). These methods as well as other methods known in the art of DNA amplification may be used in the practice of the present disclosure.
[0106] A “polynucleotide” refers to a polymer composed of many nucleotide monomers covalently bonded in a chain. Such “polynucleotides” includes DNA, RNA, modified oligo nucleotides (e.g., oligonucleotides comprising bases that are not typical to biological RNA or DNA, such as 2'-0-methylated oligonucleotides), and the like. In some embodiments, a nucleic acid or polynucleotide can be single-stranded, double-stranded, multi-stranded, or combinations thereof. Unless otherwise indicated, a particular nucleic acid or polynucleotide of the presentAttorney Docket No: PAT-109797-WO-SEC-1
[0107] disclosure optionally comprises or encodes complementary polynucleotides, in addition to any polynucleotide explicitly indicated.
[0108] "Polynucleotide of interest" or “nucleotide sequence of interest” refers to any polynucleotide which, when transferred to an organism, e.g., a plant, confers upon the organism a desired characteristic such as insect resistance, disease resistance, improved nutritional value, improved performance in an industrial process, production of commercially valuable enzymes or metabolites or altered reproductive capability.
[0109] A "promoter" is an untranslated DNA sequence upstream of the coding region that contains the binding site for RNA polymerase and initiates transcription of the DNA. The promoter region may also include other elements that act as regulators of gene expression.
[0110] “Preferred expression” is the expression of gene products that are preferably expressed at a higher level in one or a few plant tissues (spatial limitation) and / or to one or a few plant developmental stages (temporal limitation) while in other tissues / developmental stages there is a relatively low level of expression.
[0111] As used herein, the terms “progeny” and “progeny plant” refer to a plant generated from a vegetative or sexual reproduction from one or more parent plants. A progeny plant may be obtained by cloning or selfing a single parent plant (i.e., the same plant acts as the donor of both male and female gametes), or by crossing two parental plants. The descendant s) can be, for example, of the Fl, the F2, or any subsequent generation.
[0112] As used herein, the term “recombinant” refers to a non-naturally occurring DNA, protein, cell, seed, or organism that is the result of genetic engineering and as such would not normally be found in nature. A “recombinant DNA molecule” is a DNA molecule comprising a DNA sequence that is not naturally found in nature and, as such, is the result of human intervention, such as a DNA molecule comprised of at least two DNA molecules heterologous to each other.
[0113] A “recombinant protein” is a protein comprising an amino acid sequence that does not naturally occur and as such is the result of human intervention, such as an engineered protein or a chimeric protein. A recombinant cell, seed, or organism is a cell, seed, or organism comprises a heterologous or transgenic DNA, for example a transgenic cell, seed, plant, or plant part comprising a recombinant DNA molecule and therefore produced as a result of plant
[0114] transformation.Attorney Docket No: PAT-109797-WO-SEC-1
[0115] As used herein, a "recombinant plant" is a plant that would not normally exist in nature, is the result of human intervention, and contains a cisgenic nucleic acid molecule incorporated into its genome. As a result of such genomic alteration, the recombinant plant is distinct from the related wild-type plant.
[0116] A "regulatory sequence” or “regulatory element,” and the like, is understood herein to refer to a nucleotide sequence that controls the expression of an operably associated coding sequence by providing the recognition for RNA polymerase and other factors required for proper transcription and is typically located upstream (5') to the coding sequence whose expression it regulates. "Regulatory sequences" include 5' regulatory sequences located proximal and more distal elements upstream of the associated coding region, which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. "Regulatory sequences" may further include 3' sequences, including 3' non-translated and / or 3' non-transcribed sequences, located downstream of the associated coding region, and can include a transcription termination site, i.e. terminators. "Regulatory sequences" may include enhancers, promoters, untranslated leader sequences, introns, and polyadenylation signal sequences. They include natural and synthetic sequences as well as sequences that may be a combination of synthetic and natural sequences. An "enhancer" is a DNA sequence that can stimulate promoter activity and may be an innate element of the promoter that enhances the level or tissue specificity of a promoter. It is capable of operating in both orientations (normal or flipped), and is capable of functioning even when moved either upstream or downstream from the promoter. The meaning of the term "regulatory sequences" includes "transcription initiation" or "promoter" sequences and "promoter regulatory sequences." These terms may herein be used interchangeably.
[0117] “Regulatory elements" refer to sequences involved in controlling the expression of a nucleotide sequence. Regulatory elements comprise a promoter operably linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence. “Selectable marker” or “selection marker” or “selectable marker gene” is a nucleic acid sequence encoding a gene product that confers a selectable phenotype, typically resistance or tolerance to a selective agent (e.g., herbicide, antibiotic, or metabolite), such that cells expressing the marker can be distinguished and recovered from cells lacking the marker under selective conditions. Selection markers used routinely in transformation include the nptll gene, which confers resistance to kanamycin andAttorney Docket No: PAT-109797-WO-SEC-1
[0118] related antibiotics (Messing & Vierra Gene 19: 259-268 (1982); Bevan et al., Nature 304:184-187 (1983)), the pat and bar genes, which confer resistance to the herbicide glufosinate (also called phosphinothricin; see White et al., Nucl. Acids Res 18: 1062 (1990), Spencer et al. Theor. Appl. Genet 79: 625-631 (1990) and U.S. Patent Nos. 5,561,236 and 5,276,268), the hph gene, which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, Mol. Cell Biol. 4: 2929-2931), and the dhfr gene, which confers resistance to methatrexate (Bourouis et al., EMBO J. 2(7): 1099-1104 (1983)), the EPSPS gene, which confers resistance to glyphosate (U.S. Patent Nos. 4,940,935 and 5,188,642), the glyphosate N-acetyltransferase (GAT) gene, which also confers resistance to glyphosate (Castle et al. (2004) Science, 304:1151-1154; U.S. Patent App. Pub. Nos. 20070004912, 20050246798, and 20050060767); and the mannose-6-phosphate isomerase gene, which provides the ability to metabolize mannose (U.S. Patent Nos.
[0119] 5,767,378 and 5,994,629). Other selectable markers include nucleotide sequences encoding green fluorescent protein (GFP), 0 -glucuronidase (GUS), phosphinothricin N-acetyl transferase (PAT, BAR), neomycin phosphotransferase, hygromycin phosphotransferase, 0-lactamase, catechol dioxygenase, a-amylase, tyrosinase, 0-galactosidase, luciferase, aequorin, EPSP synthase, nitrilase, acetolactate synthase (ALS), dihydrofolate reductase (DHFR), dalapon dehalogenase and anthranilate synthase.
[0120] Examples of selectable markers further include, but are not limited to, DNA segments that comprise restriction enzyme sites; DNA segments that encode products which provide resistance against otherwise toxic compounds including antibiotics, such as, spectinomycin, ampicillin, kanamycin, tetracycline, Basta, neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT)); DNA segments that encode products which are otherwise lacking in the recipient cell (e.g., tRNA genes, auxotrophic markers); DNA segments that encode products which can be readily identified (e g., phenotypic markers such as 0-galactosidase, GUS; fluorescent proteins such as green fluorescent protein (GFP), cyan (CFP), yellow (YFP), red (RFP), and cell surface proteins); genes that confer resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). See for example, Yarranton, (1992) Curr Opin Biotech 3:506-11; Christopherson et al., (1992) Proc. Natl. Acad. Sci. USA 89:6314-8; Yao et al.,
[0121] (1992) Cell 71:63-72; Reznikoff, (1992) Mol Microbiol 6:2419-22; Hu et al., (1987) Cell 48:555-66; Brown et al., (1987) Cell 49:603-12; Figge et al., (1988) Cell 52:713-22; Deuschle et al.,Attorney Docket No: PAT-109797-WO-SEC-1
[0122] (1989) Proc. Natl. Acad. Sci. USA 86:5400-4; Fuerst et al., (1989) Proc. Natl. Acad. Set.
[0123] USA 86:2549-53; Deuschle et al., (1990) Science 248:480-3; Gossen, (1993) Ph.D. Thesis, University of Heidelberg; Reines et al., (1993) Proc. Natl. Acad. Sci. USA 90:1917-21; Labow et al., (1990) Mol Cell Biol 10:3343-56; Zambretti et al., (1992) Proc. Natl. Acad. Sci.
[0124] USA 89:3952-6; Baim et al., (1991) Proc. Natl. Acad. Sci. USA 88:5072-6; Wyborski et al., (1991) Nucleic Acids Res 19:4647-53; Hillen and Wissman, (1989) Topics Mol Struc
[0125] Biol 10:143-62; Degenkolb et al., (\99\ ) Anlimicrob Agents Chemother 35:1591-5; Kleinschnidt et al., (1988) Biochemistry 27: 1094-104; Bonin, (1993) Ph.D. Thesis, University of Heidelberg; Gossen et al., (1992) Proc. Natl. Acad. Sci. USA 89:5547-51; Oliva et al., (1992)24wfr' / wcroZ> Agents Chemother 36:913-9; Hlavka et al., (1985) Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al., (1988) Nature 334:721-4.
[0126] A transformed plant cell, callus, tissue or plant may be identified and isolated by selecting or screening the plant material for traits encoded by the selectable marker gene present on the transforming DNA. For instance, selection may be performed by growing the transformed plant material on media containing an inhibitory amount of the antibiotic or herbicide to which the selectable marker confers resistance. Further, transformed plants and plant cells may be identified by screening for the activities of any visible marker genes (e.g., the 0 -glucuronidase, luciferase, B or C 1 genes) that may be present on the recombinant nucleic acid constructs. Such selection and screening methodologies are well known to those skilled in the art.
[0127] The term “counter selection marker" refers to a polynucleotide sequence that confers a selective disadvantage on a host cell. Examples of counter selection markers include sacB, rpsL, tetAR, pheS, thyA, gata-1, ccdB, kid, and barnase (Bernard, 1995, Journal / Gene, 162:159-160; Bernard et al., 1994. Journal / Gene , 148: 71-74; Gabant et al., 1997, Joumal / Biotechniques, 23: 938-941; Gabant et al., 1998, Journal / Gene, 207: 8792; Gababt et al., 2000, Joumal / Biotechniques, 28:784-788; Galvao and de Lorenzo, 2005, Joumal / Appl Environ Microbiol, 71: 883-892; Hartzog et al., 2005, Joumal / Yeat, 22: 789-798; Knipfer et al., 1997, Joumal / Plasmid, 37: 129-140; Reyrat et al., 1998, Joumal / Infect Immun, 66: 4011-4017;
[0128] Soderholm et al., 2001, Journal / Biotechniques, 31: 306-310, 312; Tamura et al., 2005, Journal / Appl Environ Microbiol, 71: 587-590; Yazynin et al., 1999, Joumal / FEBS Lett, 452: 351-354). Upon introduction into a host cell, counter selection markers confer a selective disadvantage to the host cell. For example, they may confer the host cell with sensitivity to aAttorney Docket No: PAT-109797-WO-SEC-1
[0129] compound that can be added to the host cell's growth environment. As another example, they may cause a host cell with a particular genotype to be killed but not a host cell with a different genotype. In still another example, expression of the counter selection marker in a host cell may result in a toxic compound (e.g., toxic enzyme) being produced in the host cell, resulting in the host cells not being able to survive.
[0130] “Specific expression” is the expression of gene products that is limited to one or a few plant tissues (spatial limitation) and / or to one or a few plant developmental stages (temporal limitation).
[0131] “Tissue-specific promoter” refers to regulated promoters that are not expressed in all plant cells but only in one or more cell types in specific organs (such as leaves, roots or seeds), specific tissues (such as embryo or cotyledon), or specific cell types (such as leaf parenchyma or seed storage cells). These also include promoters that are temporally regulated, such as in early or late embryogenesis, during fruit ripening in developing seeds or fruit, in fully differentiated leaf, or at the onset of senescence.
[0132] A “transcriptional cassette” will comprise in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a nucleotide sequence of interest, and a transcriptional and translational termination region functional in plants. In various embodiments, the termination region is native with the transcriptional initiation region and the nucleotide sequence of interest.
[0133] The “transcription initiation site” is the position surrounding the first nucleotide that is part of the transcribed sequence, which is also defined as position +1. With respect to this site all other sequences of the gene and its controlling regions are numbered. Downstream sequences (i.e. further protein encoding sequences in the 3’ direction) are denominated positive, while upstream sequences (mostly of the controlling regions in the 5' direction) are denominated negative.
[0134] "Stable transformation" in the context of a polynucleotide means that a polynucleotide is introduced into the cell and is integrated into the genome of the cell. Stable transformation of a cell can be detected by, for example, a Southern blot hybridization assay of genomic DNA of the cell with nucleic acid sequences which specifically hybridize with a nucleotide sequence of a nucleic acid molecule introduced into an organism (e.g., a plant). Stable transformation of a cell can also be detected by, for example, a Northern blot hybridization assay of RNA of the cell withAttorney Docket No: PAT-109797-WO-SEC-1
[0135] nucleic acid sequences which specifically hybridize with a nucleotide sequence of a nucleic acid molecule introduced into a plant or other organism. Stable transformation of a cell can also be detected by, e.g., a polymerase chain reaction (PCR) or other amplification reaction as are well known in the art, employing specific primer sequences that hybridize with target sequence(s) of a nucleic acid molecule, resulting in amplification of the target sequence(s), which can be detected according to standard methods. Transformation can also be detected by direct sequencing and / or hybridization protocols well known in the art.
[0136] "Transformation" is a process for introducing a nucleic acid, such as a cisgenic nucleic acid, into a host cell or organism. In particular embodiments, "transformation" means the stable integration of a DNA molecule into the genome (nuclear or plastid) of an organism of interest.
[0137] "Transformed / cisgenic / recombinant" refers to a host organism, such as a plant, into which a cisgenic nucleic acid molecule has been introduced. The nucleic acid molecule is stably integrated into the genome of the host. Transformed cells, tissues, or plants are understood to encompass not only the end product of a transformation process, but also cisgenic progeny thereof. A "non-transformed", "non-cisgenic", or "non recombinant" host refers to a wild-type organism, e.g., a plant, which does not contain the cisgenic nucleic acid molecule.
[0138] “Vector” is defined to include, inter alia, any plasmid, cosmid, phage or Agrobacterium binary vector in double or single stranded linear or circular form which may or may not be self-transmissible or mobilizable, and which can transform prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication). Also included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eukaryotic (e.g. higher plant, mammalian, yeast or fungal cells).
[0139] Cisgenic Expression Cassettes and Regulatory Elements
[0140] In the field of agricultural biotechnology, plants developed utilizing cisgenic and intragenic technologies offer advantages in bringing products to market faster since, in many countries, these plants are not regulated or the regulatory process is simplified relative to a transgenic plant product (Cardi T (2016) Plant Breed 135(2): 139-147). However, current strategies for generating cisgenic or intragenic events mostly depend on Agrobacterium-mediatedAttorney Docket No: PAT-109797-WO-SEC-1
[0141] transformation which requires the use of T-DNA border repeat sequences to initiate T-DNA production and transfer. Due to the inconsistency of T-DNA transfer, transformation events in plants frequently result in inserts that contain most or all of the nucleotide T-DNA border sequences (Vanblaere et al. (2014) Plant Biotechnol J 12(1 ):2— 9; Holme et al (2020) Front Plant Sci 11 : 592139) and even some portions of the vector backbone sequence. The presence of such sequences is undesirable .
[0142] Thus, there is a need for innovative cisgenic and intragenic vector systems that can efficiently and precisely introduce desired traits while maintaining the integrity of the host organism's genome. Such advancements could significantly enhance the development of improved crop varieties and other applications in biotechnology. This present disclosure addresses these challenges by presenting a novel cisgenic vector system designed to optimize gene delivery and expression in target organisms, while eliminating the introduction of vector backbone (foreign) DNA and border sequences.
[0143] In various embodiments, the methods and compositions provide herein generate or comprise a 5’ cisgenic junction having genomic plant DNA contiguous with the cisgenic nucleotide sequence of interest. For the purposes of the present invention, “contiguous” refers to two elements (e.g., nucleic acids) being immediately adjacent to one another with no intervening elements (e.g., intervening nucleotides) between the two elements. The resulting cisgenic plant has a 5’ cisgenic junction in its genome wherein there is no foreign nucleotide sequence (e.g., backbone or border sequence) between the genomic plant DNA and the cisgenic nucleotide sequence of interest.
[0144] In various embodiments, the methods and compositions provide herein generate or comprise a 3’ cisgenic junction having genomic plant DNA contiguous with the cisgenic nucleotide sequence of interest. For the purposes of the present invention, “contiguous” refers to two elements (e.g., nucleic acids) being immediately adjacent to one another with no intervening elements (e.g., intervening nucleotides) between the two elements. The resulting cisgenic plant has a 3’ cisgenic junction in its genome wherein there is no foreign nucleotide sequence (e.g., backbone or border sequence) between the genomic plant DNA and the cisgenic nucleotide sequence of interest.
[0145] Thus, provided herein are expression constructs (or vectors) for the introduction of cisgenic or intragenic expression cassettes comprising one or more nucleotide sequences ofAttorney Docket No: PAT-109797-WO-SEC-1
[0146] interest, wherein use of the expression construct for introducing said expression cassettes results in the integration of the cisgenic nucleotide sequence of interest into the host cell without introducing any residual foreign or backbone DNA into the cell. In various embodiments, the expression construct comprises a T-DNA having a right border sequence, an expression cassette comprising a cisgenic nucleotide sequence of interest, and a left border sequence.
[0147] A T-DNA (transfer DNA) vector is a type of plasmid used in plant genetic engineering, particularly for gene transfer mediated by Agrobacterium tumefaciens. It leverages the natural ability of Agrobacterium to transfer a segment of its DNA (T-DNA) into the genome of plant cells. In genetic engineering, this T-DNA region of the plasmid is modified to carry the gene of interest along with (optionally) selectable markers and regulatory sequences. The T-DNA vector contains left and right border sequences, the gene(s) of interest, and, optionally, selectable marker genes and / or promoter and terminator sequences. Once transformed into the plant genome, the T-DNA is stably integrated, allowing the gene of interest to be expressed and inherited by subsequent plant generations.
[0148] A T-DNA vector may comprise an expression cassette comprising one or more T-DNAs wherein each T-DNA comprises a right border (RB) sequence and a left border (LB) sequence flanking a gene of interest and optionally one or more regulatory elements, such as promoters, terminators, introns, and UTRs, for driving expression of the gene of interest in a host cell upon transformation with the T-DNA vector and upon integration of the T-DNA into the genome of the host cell. Integration of the T-DNA may lead to truncation of the T-DNA borders and the production of fdler, undesired DNA adjacent to the gene of interest.
[0149] The left border (LB) sequence is a specific region in the T-DNA of Agrobacterium tumefaciens plasmids that marks the boundary for DNA transfer into plant cells. These left border sequences act as recognition sites where the virulence (vir) proteins (for example, the VirDl and VirD2 proteins) of Agrobacterium cleave and prepare the T-DNA region for transfer into the plant cell. The left border sequence consists of a well-defined sequence of nucleotides, usually around 24 to 25 base pairs long, and is recognized by the bacterial machinery during the transfer process. In some embodiments, the left border sequence is derived from the Agrobacterium Ti plasmid. Exemplary left border sequences include, but are not limited to, the left border sequences of nopaline synthase and octopine synthase (see, for example, the left border sequences set forth in SEQ ID NOS: 1-3, or their reverse complement; see alsoAttorney Docket No: PAT-109797-WO-SEC-1
[0150] Zambryski et al. 1980, Science, 209:1385-1391; Depicker et al., 1982, J. Mol. Appl. Genet. 1 (6), 561-573).
[0151] The right border (RB) sequence in T-DNA is a specific region of the Agrobacterium Ti plasmid that, along with the left border, defines the boundaries of the DNA transferred into the plant genome. Like the left border, the right border is about 24 to 25 base pairs long and plays a crucial role in the T-DNA transfer process. Exemplary right border sequences include, but are not limited to, the right border sequences of nopaline synthase and octopine synthase (see, for example, the right border sequences set forth in SEQ ID NOS: 4-6, or their reverse complement).
[0152] The left border and right border sequences are also known as “imperfect repeats” as they typically are similar, but not identical. This allows the vir proteins to easily recognize a border sequence while being able to distinguish the right border of the T-DNA from the left border. The vir proteins act as site-specific endonucleases to generate a single-stranded nick at a specific location within the recognized border sequence.
[0153] These right border sequences are recognized by the Agrobacterium virulence (vir) proteins (for example, the VirDl and VirD2 proteins), and they help define the region of the T-DNAthat will be transferred into the plant genome. The RB sequence is the point where the T-DNA is cleaved, allowing the segment of DNA between the right and left borders to be transferred into the plant.
[0154] Integration of T-DNA can lead to truncation of the T-DNA right and / or left borders and the production of filler, undesired DNA adjacent to the gene of interest. As non-limiting examples embodiment, the Agrobacterium machinery may initiate cleavage and DNA transfer at a specific site within the right border sequence (for example, a TCA or an ACC sequence within the right border sequence, or a reverse complement thereof) and initiate cleavage and DNA transfer at that location. During integration of the T-DNA, the cleavage site (e.g., the TCA or ACC or the reverse complement thereof) may be truncated or removed, as well as one or more downstream nucleotides within the T-DNA (including within the right border sequence). In particular embodiments, up to 5, 10, 20, 25, or up to 50bp of the cut site in the right border sequence may be truncated during integration.
[0155] As another non-limiting example embodiment, the Agrobacterium machinery may cleave at a specific site without the left border sequence (for example, a CTGCCA sequence within the left border sequence, or a reverse complement thereof). During integration of the T-DNA, anyAttorney Docket No: PAT-109797-WO-SEC-1
[0156] portion of the cleavage site may be truncated or removed, as well as one or more nucleotides upstream thereof within the T-DNA (including within the left border sequence). In particular embodiments, up to 5, 10, 20, 25, or up to 50bp upstream of the cut site in the left border sequence may be truncated during integration.
[0157] In particular embodiments, up to 5, 10, 20, 25, 50 or up to lOObp of the sequence may be truncated during integration. It will be appreciated that a variety of T-DNAs are known in the art and that the left and right border sequences that are recognized, as well as the unique cleavage site within a border sequence, as well as the number of nucleotides that are truncated relative to the cut site during integration can vary on account of this diversity (see, for example, Bundock el al. PNAS (1996), vol. 93 (26): 15272-15275; and Kleinboelting et al. Molecular Plant (2015), vol. 8 (11): 1651-1664. In various embodiments, transformation of a plant cell with the expression constructs comprising the T-DNA described herein results in at least one plant cell having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming at least one cisgenic junction. A “cisgenic junction” defines the insertion site of the cisgenic nucleotide sequence of interest in the plant genome, whereby the first region of the cisgenic junction comprises the plants genomic DNA and the second region of the cisgenic junction comprises the cisgenic nucleotide sequence of interest. The cisgenic junction only contains nucleotide sequences that are native genomic sequences of the transformed plant (or sexually compatible species thereof) and are found in the cisgenic nucleotide sequence of interest.
[0158] A 5’ cisgenic junction occurs at the site of integration of the right border T-DNA into the genome of the plant. A3’ cisgenic junction occurs at the site of integration of the left border T-DNA into the genome of the plant. The 5’ or 3’ cisgenic junction can comprise at least 3, at least 4, at least 5, 10, 20, 50, 100, 200, 500, 700, 1000, 2000, 5000, 7000, 9000, 10000 or more nucleotides from the genomic DNA of the recipient plant and at least 3, at least 4, at least 5, 10, 20, 50, 100, 200, 500, 700, 1000, 2000, 5000, 7000, 9000, 10000 or more from the cisgenic expression cassette comprising the nucleotide sequence of interest.
[0159] In specific embodiments, the 5’ cisgenic junction comprises a right border sequence having a 5’ portion and 3’ portion, wherein the 3’ portion of the right border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest, preferably within the promoter region of the nucleotide sequenceAttorney Docket No: PAT-109797-WO-SEC-1
[0160] of interest. This strategy takes advantage of the fact that, for T-DNA insertion in a host genome, the virulence gene virD only requires 3 bp from the right border sequence for integration. Thus, transformed cells can be selected as described elsewhere herein for events in which only that portion of the right border sequence is inserted into the host genome and that portion of the right border sequence makes up the 5’ cisgenic junction. In this embodiment, the regulatory region of the native sequence is evaluated to identify three consecutive nucleotides that are identical to the three consecutive nucleotides at the 3’ end of the right border sequence of the T-DNA. For example, if the 3’ end of the right border sequence in the T-DNA is the nucleotide sequence TCA, the regulatory region of the native nucleotide sequence of interest may be extended upstream of the transcription start site to include the naturally occurring TCA sequence of the native nucleotide sequence of interest and to further include the region of regulatory sequence that is immediately downstream of the nucleotide sequence TCA. In this scenario, since the 3’ end of the right border is identical to what naturally occurs in the nucleotide sequence of interest at this junction, the 5’ cisgenic junction is considered to be free of foreign or backbone DNA. In other words, the TCA is shared between the right border sequence in the T-DNA and the cisgene sequence to be inserted. In other examples, the three consecutive nucleotides comprise ACC and the regulatory region of the native nucleotide sequence of interest may be extended upstream of the transcription start site to include the naturally occurring ACC sequence of the native nucleotide sequence of interest and to further include the region of regulatory sequence that is immediately downstream of the nucleotide sequence ACC. It will be appreciated that based on the strand selected, the sequence may be reverse complement of those discussed herein.
[0161] In alternate embodiments, based on the location of the TCA or ACC within the 5’ regulatory region upstream of the transcription start site, one of more nucleotides (e.g., 3, 4, 5, 6, 10, 15, 20, 22, 25, 30, 32, 33, 35, 40, 50 bp or more) of the 5’ regulatory region may be removed until the 3’ end of the right border sequence comprises the naturally occurring TCA or ACC of the 5’ regulatory region.
[0162] In the specific embodiment depicted at FIGS. 1-2, the desired 5’ cisgenic junction comprising no foreign or vector backbone DNA is created through the use of an expression construct wherein the TCA for the T-DNA right border sequence is provided by extending the 5’ regulatory region of the cisgenic nucleotide sequence of interest, upstream of the transcription start site (TSS), until a naturally occurring TCA is found within the native sequence. The T-DNAAttorney Docket No: PAT-109797-WO-SEC-1
[0163] right border sequence is then placed contiguous (that is, immediately adjacent) to the extended native regulatory region sequence of the cisgenic nucleotide sequence of interest such that the TCA from the cisgenic sequence is the same as the TCA of the 3’ portion of the right border sequence. This creates a heterologous right border having a contiguous 5’ and 3’ portion wherein the 5’ portion consists of T-DNA right border sequence (shortened by 3 consecutive nucleotides) and wherein the 3’ portion of the heterologous right border comprises three nucleotides which are identical to the three nucleotides located within the cisgenic nucleotide sequence of interest (and in particular to the 5’ end of the extended regulatory sequence of the cisgenic nucleotide sequence of interest). When the expression construct is transformed into a plant cell, the resulting nicking at the TCA sequence of the heterologous right border results in a plant cell having the cisgenic nucleotide sequence of interest inserted with no undesired DNA sequences from the vector. Even if any further truncation occurs downstream of the TCA during integration, the 5’ cisgenic junction will not include any filler DNA.
[0164] As discussed earlier, based on the diversity of T-DNA border sequences, in other embodiments, the number of consecutive nucleotides of the heterologous right border sequence that are identical to nucleotides within the cisgenic sequence may be larger. For example, the right border sequence may be shortened at the 3’ end by 3, 4, 5, 6, or 10 nucleotides and the identical 3, 4, 5, 6, or 10 nucleotides in cisgenic nucleotide sequence may be positioned adjacent to it to create a heterologous right border sequence. For the purposes of the present disclosure, the “5' non-translated sequences” (or 5' untranslated sequences or 5 -UTR) means DNA sequences corresponding to the mRNA region that extends from the transcriptional start site (TSS) to the -1 position of the coding sequence (CDS), excluding any intron sequences within this region. The 5'-UTR sequence is derived from the native gene and may include at least 50, 100, 200, 500, 700, 1000, 2000, 5000, 7000, 9000, or more, nucleotides, from the region immediately upstream of the start codon of the nucleotide sequence of interest. In specific embodiments, the 5’ cisgenic junction is located from 5 to 100, from 10-50, from 100 to 200, from 200 to 300, from 300 to 400, from 400 to 500, from 500 to 1 kb, or further, from the translation initiation codon of the cisgenic nucleotide sequence of interest.
[0165] In certain embodiments, the 3’ cisgenic junction comprises a left border sequence having a 5’ portion and 3’ portion, wherein the 5’ portion of the left border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenicAttorney Docket No: PAT-109797-WO-SEC-1
[0166] nucleotide sequence of interest, preferably within the 3’-UTR of the nucleotide sequence of interest. This strategy takes advantage of the natural truncations that occur at the left border in the process of T-DNA insertion of a nucleotide sequence of interest in a recipient host cell genome. Truncations may occur at any point in the left border region, and the integrated nucleotide sequence may include any or no nucleotides derived from the T-DNA left border. Thus, transformed cells can be selected as described elsewhere herein for events in which only the portion of the left border sequence that is identical to a series of consecutive nucleotides (e.g., 3, 4, 5, or more consecutive nucleotides) in the 3’-UTR of the nucleotide sequence of interest is inserted into the host genome. In some embodiments, transformed cells are selected in which none of the left border sequence is retained. In these embodiments, the 3’ regulatory region of the native sequence is evaluated to identify a series of consecutive nucleotides (e.g., 3, 4, 5, or more consecutive nucleotides) that are identical to a series of consecutive nucleotides at the 5’ end of the left border sequence of the T-DNA. For example, if the 5’ end of the left border sequence in the T-DNA is the nucleotide sequence GTTT, the regulatory region of the native nucleotide sequence of interest is extended to include the region of regulatory sequence that is immediately upstream of the nucleotide sequence GTTT. In this scenario, since the 5’ end of the left border is identical to what naturally occurs in the nucleotide sequence of interest at this junction, the insertion is considered to be free of foreign or backbone DNA.
[0167] In alternate embodiments, based on the location of the GTT or GTTT within the 3’ regulatory region downstream of the transcription end site, one of more nucleotides (e.g., 3, 4, 5, 6, 10, 15, 20, 22, 25, 30, 32, 33, 35, 40, 50 bp or more) of the 3’ regulatory region may be removed until the 5’ end of the left border sequence comprises the naturally occurring GTT of the 3’ regulatory region.
[0168] In the specific embodiment depicted at FIGS. 1-2, the desired 3’ ci sgenic junction comprising no foreign DNA is created through the use of an expression construct wherein the GTT in a heterologous left border sequence is derived from the 3’ end of the 3’ regulatory region of the cisgenic nucleotide sequence of interest. The 3’ regulatory region is extended downstream of the TES or stop codon until a naturally occurring GTT is found within the native sequence. The T-DNA left border sequence is then placed contiguous to the GTT to create a heterologous left border sequence having a contiguous 5’ and 3’ portion wherein the 3’ portion of the heterologous left border comprises the T-DNA left border sequence, and wherein the 5’ portionAttorney Docket No: PAT-109797-WO-SEC-1
[0169] of the heterologous left border comprises three nucleotides which are identical to the three nucleotides located within the cisgenic nucleotide sequence of interest (and in particular to the 3’ end of the extended regulatory sequence of the cisgenic nucleotide sequence of interest). When the expression construct is transformed into a plant cell, the VirD proteins recognize the sequence CTGCCA within the heterologous left border sequence and create a single stranded nick at that location. Truncation of 3, 5, 10, or up to lOObp upstream of the nick site can then occur. For example, during integration, the T-DNA can be truncated to remove most of the left border sequence including the GTT and further upstream. If truncation occurs including the GTT, or further upstream into the cisgenic nucleotide sequence, the resulting plant cell will have a cisgenic nucleotide sequence of interest inserted into the genome with no filler DNA from the vector.
[0170] As discussed earlier, based on the diversity of T-DNA border sequences, in other embodiments, the number of consecutive nucleotides of the heterologous left border sequence that are identical to nucleotides within the cisgenic sequence may be larger. For example, the left border sequence may be shortened at the 5’ end by 3, 4, 5, 6, or 10 nucleotides and the identical 3, 4, 5, 6, or 10 nucleotides in cisgenic nucleotide sequence may be positioned adjacent to it to create a heterologous left border sequence.
[0171] For the purposes of the present disclosure, the “3' non-translated sequences” (or 3' untranslated sequences or 3'-UTR) means DNA sequences corresponding to the mRNA region that extends from the stop codon of nucleotide sequence of interest (+1) to the -1 position of the transcriptional end site (TES), excluding any intron sequences within this region. It is located downstream of a nucleotide sequence of interest and include sequences encoding polyadenylation and other regulatory signals capable of affecting mRNA processing or gene expression. The 3'-UTR sequence is derived from the native gene and may include at least 50, 100, 200, 500, 700, 1000, 2000, 5000, 7000, 9000, or more, nucleotides, from the region immediately downstream of the TES of the nucleotide sequence of interest.
[0172] In some embodiments, the expression construct comprises a single T-DNA comprising an expression cassette comprising a cisgenic nucleotide sequence of interest. In other embodiments, the expression construct comprises a first and a second T-DNA, wherein the second T-DNA comprises a second or subsequent expression cassette comprising a second or subsequent cisgenic nucleotide sequence of interest or comprises a selectable marker gene as disclosedAttorney Docket No: PAT-109797-WO-SEC-1
[0173] elsewhere herein. The expression construct may further comprise a spacer region between the first and second T-DNA, and each nucleotide sequence of interest is flanked by separate T-DNA borders. The first and second nucleotide sequence of interest may be genetically linked and inherited together, or may be segregable in a manner that allows for crossing and selection of subsequent generations that contain one or the other of the nucleotide sequences of interest. Segregation can facilitate, for example, removal of a selectable marker gene from a plant population.
[0174] Cisgenic Nucleotide Sequence of Interest
[0175] The cisgenic nucleotide sequence of interest that is to be integrated into the genome of a plant cell is a nucleic acid sequence that naturally exists in, originates from, or belongs to the genome of a plant that is to be transformed, or from a plant or species that is sexually compatible with the plant species that is to be transformed. In embodiments, the cisgenic nucleotide sequence of interest encodes a desirable trait such as encoding a protein that confers, for example, insect resistance, pathogen resistance (e.g., fungal, viral, or bacterial pathogen resistance), disease resistance, or herbicide resistance, or other desirable agronomic traits of interest including, but not limited to, traits associated with high or low oil content; traits associated with increased protein content, increased digestibility; balanced or rebalanced amino acid content; improved drought resistance, improved heat resistance, improved salinity resistance, modified maturity and / or flowering time, and high energy content. Still other traits may be possible based on the plant from which the cisgenic nucleotide sequence of interest is derived and / or based on the plant being transformed with the cisgenic nucleotide sequence of interest.Non-limiting examples of cisgenic nucleotide sequences encoding traits that originate from, and are transformed into, a soybean plant (such as from Glycine max or a Glycine species that is sexually compatible with Glycine max) are publicly available on soybase(.)org and include: genes associated with flowering time and maturity in soybean such as El, E2, E3, E4, FT2a (or E9), FT5a (see, for example, WO2023168691, WO2024102277, WO2025145425A1, WO2018075649A1, US12110495B2); genes associated with seed size, yield, plant architecture (or stem termination) and / or pod size such as Dtl, Dt2 and Sweet proteins (e.g., GmSWEET6, 10a, 10b, 39, etc.) (see, for example, CN110669782B, CN108467868B, and CN113265403 A), genes associated with abiotic stress tolerance including drought, heat, and salinity tolerance suchAttorney Docket No: PAT-109797-WO-SEC-1
[0176] as DREB 1 , DREB2, NAC20, NAC 11 , SOS 1 , HKT 1 , and WRK Y family members (see for example W02009013750A2, US10787677B2, W02005033318A2).
[0177] Non-limiting examples of cisgenic nucleotide sequences encoding traits that originate from, and are transformed into, a soybean plant (such as from Glycine max or a Glycine species that is sexually compatible with Glycine max) include disease resistance genes including genes responsible for Asian Soybean resistance, soybean cyst nematode resistance, bacterial resistance, and viral resistance such as Rpsl-8, Rhgl / 4, Rgl, Rpp6907, TirA, TirB, Rg21, Rg22, Rg30, Rg28, Fitl, Rpp2, Rg3a / b, Rg31, Rg32, Rg33, Rg34, Rg35, Rppl-5 (see, for example, WO2013078153A1, W02019103918, W02021000878, W02021022022, WO2021260673, WO2021263249, WO2022173659 WO2022159341 , US 11492637, US11530419; US10842097, WO2022140257, WO2024107598 WO2024107597, WO2024158975).
[0178] As described in the examples herein, specific embodiments of cisgenic expression constructs for transformation into a soybean plant cell comprise cisgenic nucleotide sequences encoding a disease resistance trait, such as the sequences of SEQ ID NOS: 7-10. One or more of the cisgenic nucleotide sequences are derived from Glycine max or from a wild Glycine species that is sexually compatible with Glycine max, such as from Glycine tomentella.
[0179] Selectable marker genes
[0180] In certain embodiments, the expression construct comprises at least a first T-DNA containing an expression cassette comprising a cisgenic nucleotide sequence of interest and at least a second T-DNA comprising a selectable marker gene for the selection of transformed cells or tissues. Selectable marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin, 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) or acetolactate synthase (ALS). Selection markers used routinely in transformation include the nptll gene, which confers resistance to kanamycin and related antibiotics (Messing & Vierra Gene 19: 259-268 (1982); Bevan et al., Nature 304:184-187 (1983)), the pat and bar genes, which confer resistance to the herbicide glufosinate (also called phosphinothricin; see White etal., Nucl. Acids Res 18: 1062 (1990), Spencer et al. Theor. Appl. Genet 79: 625-631 (1990) and U.S. Patent Nos. 5,561,236 and 5,276,268), the hph gene, which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, Mol. Cell Biol. 4: 2929-2931), and the dhfr gene, which confers resistance to methatrexate (Bourouis et al., EMBOAttorney Docket No: PAT-109797-WO-SEC-1
[0181] J. 2(7): 1099-1104 (1983)), the EPSPS gene, which confers resistance to glyphosate (U.S. Patent Nos. 4,940,935 and 5,188,642), the glyphosate N-acetyltransferase (GAT) gene, which also confers resistance to glyphosate (Castle e / a / . (2004) Science, 304:1151-1154; U.S. Patent App. Pub. Nos. 20070004912, 20050246798, and 20050060767); and the mannose-6-phosphate isomerase gene, which provides the ability to metabolize mannose (U.S. Patent Nos. 5,767,378 and 5,994,629).
[0182] Counter selection marker genes
[0183] In certain embodiments, the expression construct comprises, in a spacer region between a first T-DNA containing an expression cassette comprising a cisgenic nucleotide sequence of interest and a second T-DNA comprising a selectable marker gene for the selection of transformed cells or tissues, a third nucleotide sequence encoding a counter selection marker gene for the counterselection of selected transformed cells or tissues. Example counter selection markers include sacB, rpsL, tetAR, pheS, thy A, gata-1, ccdB, kid, and barnase (Bernard, 1995, Joumal / Gene, 162:159-160; Bernard et al., 1994. Journal / Gene , 148: 71-74; Gabant et al., 1997, Journal / Biotechniques, 23: 938-941; Gabant et al., 1998, Joumal / Gene, 207: 8792; Gababt et al., 2000, Journal / Biotechniques, 28:784-788; Galvao and de Lorenzo, 2005, Journal / Appl Environ Microbiol, 71: 883-892; Elartzog et al., 2005, Joumal / Yeat, 22: 789-798; Knipfer et al., 1997, Joumal / Plasmid, 37: 129-140; Reyrat et al., 1998, Joumal / Infect Immun, 66: 4011-4017;
[0184] Soderholm et al., 2001, Journal / Biotechniques, 31: 306-310, 312; Tamura et al., 2005, Journal / Appl Environ Microbiol, 71: 587-590; Yazynin et al., 1999, Joumal / FEBS Lett, 452: 351-354). Upon introduction into a host cell, counter selection markers confer a selective disadvantage to the host cell. For example, they may confer the host cell with sensitivity to a compound that can be added to the host cell's growth environment. As another example, they may cause a host cell with a particular genotype to be killed but not a host cell with a different genotype. In still another example, expression of the counter selection marker in a host cell may result in a toxic compound (e.g., toxic enzyme) being produced in the host cell, resulting in the host cells not being able to survive.
[0185] In specific embodiments, the counter selection marker used in the expression construct is the barnase gene which produces Barnase, an extracellular ribonuclease (RNAse), in the host cell. The cytotoxic enzyme causes RNA degradation in the host cell, precipitating cell death. AsAttorney Docket No: PAT-109797-WO-SEC-1
[0186] elaborated further herein with reference to FIGS. 3A-B, transformation events comprising the counterselection marker (such as events comprising the counterselection marker only, or events comprising the counterselection marker with one or more of the cisgenic nucleotide sequence of interest, or the selection marker), do no survive and are thereby counter selected for.
[0187] Plants, Plant Cells, and Plant Parts
[0188] Plants, plant parts, plant cells and seed are provided which comprise a first region comprising genomic DNA of the plant and a second region comprising a cisgenic nucleotide sequence of interest.
[0189] The cisgenic nucleotide sequence of interest may be introduced into any plant species, including, but not limited to, monocots and dicots. Examples of plants of interest include, but are not limited to, field crops, fruits and vegetables such as canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, mangelworzel, potato, carrot, lettuce, cabbage, onion, etc. Particularly preferred genetically modified plants are soya species, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax and oilseed rape, and nut producing plants insofar as they are not already specifically mentioned. In a particularly preferred embodiment of the method the said plant is a dicot, preferably selected from the group consisting of canola, sunflower, tobacco, sugar beet, soybean, cotton, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, cabbage, onion, and is particularly preferably soybean. In further preferred embodiments the said plant is maize or rice. Preferably the plant of is soybean, rice or maize. Embodiments also include the progeny of the plant of the foregoing, and the seeds or other propagating material of such plants and progeny.
[0190] In some embodiments, a plant cell, seed, or plant part or harvest product can be obtained from the plant produced as above and the plant cell, seed, or plant part can be screened using methods disclosed above for the evidence of stable incorporation of the polynucleotide. The term “stable incorporation” refers to the integration of a nucleic acid sequence into the genome of a plant and the nucleic acid sequence is capable of being inherited by the progeny thereof.
[0191] In some embodiments, plant products can be harvested from the plant disclosed above and processed to produce processed products, such as flour, soy meal, oil, starch, and the like. These processed products are also within the scope of this disclosure provided that they compriseAttorney Docket No: PAT-109797-WO-SEC-1
[0192] a polynucleotide or polypeptide or variant or fragment thereof disclosed herein. Other soybean plant products include but are not limited to protein concentrate, protein isolate, soybean hulls, meal, flower, oil and the whole soybean itself.
[0193] Plant Transformation
[0194] Procedures for transforming plants are known in the art and are described throughout the literature. Non-limiting examples of methods for transformation of plants include transformation via bacterial -mediated nucleic acid delivery (e.g., via Agrobacterium), and viral -mediated nucleic acid delivery. General guides to various plant transformation methods known in the art include Miki et al. (“Procedures for Introducing Foreign DNA into Plants” in Methods in Plant Molecular Biology and Biotechnology, Glick, B. R. and Thompson, J. E., Eds. (CRC Press, Inc., Boca Raton, 1993), pages 67-88) and Rakowoczy-Trojanowska {Cell. Mol. Biol. Lett. 7:849-858 (2002)).
[0195] For Agrobacterium-mediated transformation, binary vectors or vectors carrying at least one T-DNA border sequence as discussed elsewhere herein are suitable. In some embodiments, transformation is undertaken with a selectable marker that may be a positive selection (Phosphomannose Isomerase; PM1), provide resistance to an antibiotic (kanamycin, hygromycin or methotrexate) or a herbicide (glyphosate or glufosinate). However, the choice of selectable marker is not critical to the disclosed method or composition, nor is the use of a selectable marker. In some example embodiments, based on the protein encoded by the cisgenic nucleotide sequence of interest, the cisgene itself may act as a selectable marker allowing for transformant selection. In some embodiments, transformation is undertaken with a counterselection marker. However, the choice of counterselection marker is not germane to the disclosed method or composition, nor is the use of a counterselection marker.
[0196] Agrobacterium-mediated transformation is a commonly used method for transforming plants because of its high efficiency of transformation and because of its broad utility with many different species. Agrobacterium-mediated transformation typically involves transfer of the binary vector carrying the nucleotide sequence of interest to an appropriate Agrobacterium strain that may depend on the complement of vir genes carried by the host Agrobacterium strain either on a co-resident Ti plasmid or chromosomally (Uknes et al. (1993) Plant Cell 5: 159-169). The transfer of the recombinant binary vector to Agrobacterium can be accomplished by a triparentalAttorney Docket No: PAT-109797-WO-SEC-1
[0197] mating procedure using Escherichia coli carrying the recombinant binary vector, a helper E. coli strain that carries a plasmid that is able to mobilize the recombinant binary vector to the target Agrobacterium strain. Alternatively, the recombinant binary vector can be transferred to Agrobacterium by nucleic acid transformation (Hofgen & Willmitzer (1988) Nucleic Acids Res.
[0198] 16:9877).
[0199] Dicots as well as monocots may be transformed using Agrobacterium. Methods for Agrobacterium-mediated transformation of rice include well known methods for rice transformation, such as those described in any of the following: European patent application EP 1198985 Al, Aldemita and Hodges (Planta 199: 612-617, 1996); Chan et al. (Plant Mol Biol 22 (3): 491-506, 1993), Hiei et al. (Plant J 6 (2): 271-282, 1994), which disclosures are incorporated by reference herein as if fully set forth. In the case of com transformation, the preferred method is as described in either Ishida et al. (Nat. Biotechnol 14(6): 745-50, 1996) or Frame et al. (Plant Physiol 129(1): 13-22, 2002), which disclosures are incorporated by reference herein as if fully set forth. Said methods are further described by way of example in B. Jenes et al, Techniques for Gene Transfer, in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds. S. D. Kung and R. Wu, Academic Press (1993) 128-143 and inPotrykus Amur Rev. Plant Physiol. Plant Molec. Biol. 42 (1991) 205-225). The nucleic acids or the construct to be expressed is preferably cloned into a vector, which is suitable for transforming Agrobacterium tumefaciens, for example pBinl9 (Bevan et al, Nucl. Acids Res. 12 (1984) 8711). Agrobacteria transformed by such a vector can then be used in known manner for the transformation of plants, such as plants used as a model, like Arabidopsis or crop plants such as, by way of example, tobacco plants, for example by immersing bruised leaves or chopped leaves in an agrobacterial solution and then culturing them in suitable media. The transformation of plants by means of Agrobacterium tumefaciens is described, for example, by Hagen and Willmitzer in Nucl. Acid Res. (1988) 16, 9877 or is known inter alia from F. F. White, Vectors for Gene Transfer in Higher Plants; in Transgenic Plants, Vol. 1, Engineering and Utilization, eds. S. D. Kung and R. Wu, Academic Press, 1993, pp. 15-38.
[0200] Transformation of a plant by recombinant Agrobacterium usually involves co cultivation of the Agrobacterium with explants from the plant and follows methods well known in the art. Transformed tissue is regenerated on selection medium carrying an antibiotic or herbicide resistance marker between the binary plasmid T-DNA borders.Attorney Docket No: PAT-109797-WO-SEC-1
[0201] Methods of selecting for transformed, cisgenic plants, plant cells or plant tissue culture are routine in the art and can be employed in the methods provided herein. For example, a recombinant vector of the instant disclosure also can include a T-DNA containing an expression cassette comprising a nucleotide sequence for a selectable marker, which can be used to select a transformed plant, plant part or plant cell. As used herein, “selectable marker” means a nucleotide sequence that when expressed imparts a distinct phenotype to the plant, plant part or plant cell expressing the marker and thus allows such transformed plants, plant parts or plant cells to be distinguished from those that do not have the marker. Such a nucleotide sequence may encode either a selectable or screenable marker, depending on whether the marker confers a trait that can be selected for by chemical means, such as by using a selective agent (e.g., an antibiotic, herbicide, or the like), or on whether the marker is simply a trait that one can identify through observation or testing, such as by screening. Of course, many examples of suitable selectable markers are known in the art and can be used in the methods described herein. Examples of selectable markers are disclosed herein.
[0202] Intact cisgenic plants can be regenerated from transformed plant cells, plant tissue culture or cultured protoplasts using any of a variety of known techniques. Plant regeneration from plant cells, plant tissue culture or cultured protoplasts is described, for example, in Evans, et al.
[0203] (Handbook of Plant Cell Cultures, Vol. 1, MacMillan Publishing Co. New York (1983)); and Vasil I. R. (ed.) Cell Culture and Somatic Cell Genetics of Plants, Acad. Press, Orlando, Vol. I (1984), and Vol. 11 (1986)).
[0204] Additionally, the genetic properties engineered into the cisgenic plants, plant parts, plant cells or seeds described above can be passed on by sexual reproduction or vegetative growth and therefore can be maintained and propagated in progeny plants. Generally, maintenance and propagation make use of known agricultural methods developed to fit specific purposes such as harvesting, sowing or tilling.
[0205] A polynucleotide therefore can be introduced into a plant, plant part or plant cell in any number of ways that are known in the art, as described above. Therefore, no particular method for introducing the DNA sequence of interest described herein into a plant is relied upon, rather any method that allows the the DNA sequence to be stably integrated into the genome of the plant can be used.Attorney Docket No: PAT-109797-WO-SEC-1
[0206] Additional embodiments include harvested products produced from the cisgenic plants or parts thereof, as well as a processed product produced from the harvested products. A harvested product can be a whole plant or any plant part, as described herein. Thus, in some embodiments, non-limiting examples of a harvested product include a seed, a fruit, a flower or part thereof (e.g., an anther, a stigma, and the like), a leaf, a stem, and the like. In other embodiments, a processed product includes, but is not limited to, a flour, meal, oil, starch, cereal, and the like produced from a harvested seed or other plant part of the disclosure, wherein said seed or other plant part comprises a nucleic acid molecule / polynucleotide / nucleotide sequence of this disclosure.
[0207] In other embodiments, an extract from a cisgenic seed or a cisgenic plant is provided, wherein the extract comprises a nucleic acid molecule, a polynucleotide, or a cisgenic nucleotide sequence of interest. Extracts from plants or plant parts can be made according to procedures well known in the art (See, de la Torre et al, Food, Agric. Environ. 2(l):84-89 (2004); F. Guidet, Nucleic Acids Res. 22(9): 1772-1773 (1994); Lipton et al., Food Agric. Immun. 12:153-164 (2000)).
[0208] Breeding and Selection
[0209] In various embodiments herein, the methods comprise crossing a donor plant comprising a first region comprising genomic DNA of the plant and a second region comprising a cisgenic nucleotide sequence of interest with a sexually compatible recipient plant. As used herein, the terms “crossing” and “breeding” refer to the fusion of gametes to produce progeny (e.g., by fertilization, such as to produce seed by pollination in plants). In some embodiments, a “cross,” “breeding,” or “cross-fertilization” is fertilization of one individual by another (e.g., crosspollination in plants). The plant disclosed herein may be a whole plant, or may be a plant cell, seed, or tissue, or a plant part such as leaf, stem, pollen, or cell that can be cultivated into a whole plant.
[0210] In some embodiments, a progeny plant created by the crossing or breeding process is repeatedly crossed back to one of its parents through a process referred to herein as “backcrossing”. In a backcrossing scheme, the “donor” parent refers to the parental plant with the desired gene or locus to be introgressed. The “recipient” parent (used one or more times) or “recurrent” parent (used two or more times) refers to the parental plant into which the gene orAttorney Docket No: PAT-109797-WO-SEC-1
[0211] locus is being introgressed. For example, see Ragot, M. et al. Marker-assisted Backcrossing: A Practical Example, in Techniques et Utilisations des Marqueurs Moleculaires Les Colloques, Vol. 72, pp. 45-56 (1995); and Openshaw et al., Marker-assisted Selection in Backcross Breeding, in Proceedings of the Symposium “Analysis of Molecular Marker Data,” pp. 41-43 (1994). The initial cross gives rise to the Fl generation. The term “BC1” refers to the second use of the recurrent parent, “BC2” refers to the third use of the recurrent parent, and so on.
[0212] Methods of Detection
[0213] Methods for detecting plants or plant cells in which a cisgenic nucleotide sequence of interest has been introduced, without the presence of vector backbone sequence, can be performed via techniques known in the art, including through the use of primers, probes, PCR, etc. In one embodiment, a PCR reaction is employed to select for plants or plant cells in which the expression cassette has been inserted without vector backbone sequence. In this embodiment, primers are designed which selectively hybridize to the 5’ cisgenic junction and / or the 3’ cisgenic junction.
[0214] The primers preferably have a sequence of between 15 and 35 nucleotides which under optimized PCR conditions “specifically recognize” a sequence within the 5’ cisgenic junction and / or the 3’ cisgenic junction so that a specific fragment (“integration fragment” or discriminating amplicon) is amplified from a nucleic acid sample comprising the cisgenic insertion. This means that only the respective junction sequences, and no other sequence in the plant genome, is amplified under optimized PCR conditions.
[0215] “Primers” as used herein are isolated nucleic acids that are annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, then extended along the target DNA strand by a polymerase, such as DNA polymerase. A primer pair comprises a “forward” primer and a “reverse” primer. Primer pairs or sets can be used for amplification of a nucleic acid molecule, for example, by the polymerase chain reaction (PCR) or other conventional nucleic-acid amplification methods.
[0216] The primers may be longer than the mentioned 15-35 consecutive nucleotides, and may, e.g., be 20, 21, 22, 23, 24, 25, 30, 35, 50, 75, 100, 150, 200 bp long or even longer. The primers may entirely consist of nucleotide sequence selected from the mentioned cisgenic junction sequences.Attorney Docket No: PAT-109797-WO-SEC-1
[0217] Moreover, suitable primers may comprise, consist or consist essentially of a nucleotide sequence spanning the junction region between the plant DNA derived sequences and the inserted DNA sequences (i.e., the cisgenic junctions). It will also be immediately clear to the skilled artisan that properly selected PCR primer pairs should also not comprise sequences complementary to each other.
[0218] The amplified junction sequences can be detected using a probe. A “probe” is an isolated nucleic acid to which is attached a detectable label or reporter molecule, such as a radioactive isotope, ligand, chemiluminescent agent, fluorescent agent, or enzyme. Probes according to the disclosure include not only deoxyribonucleic or ribonucleic acids but also polyamides and other probe materials that bind specifically to a target cisgenic junction sequence and can be used to detect the presence of that target sequence.
[0219] Probes and primers are generally 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401,Attorney Docket No: PAT-109797-WO-SEC-1
[0220] 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, or 500 polynucleotides or more in length. Such primers and probes hybridize specifically to a target sequence under high stringency hybridization conditions. Primers and probes may have complete sequence complementarity with the target sequence, although probes differing from the target sequence and which retain the ability to hybridize to target sequences may be designed by conventional methods.
[0221] "Stringent conditions" or "stringent hybridization conditions" include reference to conditions under which a probe will hybridize to its target sequence, to a detectably greater degree than to other sequences, as discussed earlier herein.
[0222] Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. Generally, high stringency hybridization and wash conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, under high stringency conditions a probe will hybridize to its target subsequence, but to no other sequences.
[0223] An example of high stringency hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formamide with 1 mg of heparin at 42°C, with the hybridization being carried out overnight. An example of very high stringency wash conditions is 0.15M NaCl at 72°C for about 15 minutes. An example of high stringency wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (see, Sambrook, infra, for a description of SSC buffer).
[0224] Exemplary hybridization conditions for the disclosed method and compositions include hybridization in 7% SDS, 0.25 M NaPO4 pH 7.2 at 67oC overnight, followed by two washings in 5% SDS, 0.20 M NaPO4 pH7.2 at 65oC for 30 minutes each wash, and two washings in 1% SDS, 0.20 M NaPO4 pH7.2 at 65oC for 30 minutes each wash. An exemplary medium stringency wash for a duplex of, e g., more than 100 nucleotides, is lx SSC at 45°C for 15Attorney Docket No: PAT-109797-WO-SEC-1
[0225] minutes. An exemplary low stringency wash for a duplex of, e g., more than 100 nucleotides, is 46x SSC at 40°C for 15 minutes.
[0226] For probes of about 10 to 50 nucleotides, high stringency conditions typically involve salt concentrations of less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is typically at least about 30°C. High stringency conditions can also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Nucleic acids that do not hybridize to each other under high stringency conditions are still substantially identical if the proteins that they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.
[0227] The following are exemplary sets of hybridization / wash conditions that may be used to hybridize nucleotide sequences that are substantially identical to reference nucleotide sequences of the invention: a reference nucleotide sequence preferably hybridizes to the reference nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 2X SSC, 0.1% SDS at 50°C, more desirably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in IX SSC, 0.1% SDS at 50°C, more desirably still in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 0.5X SSC, 0.1% SDS at 50°C, preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 50°C, more preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 0. IX SSC, 0.1% SDS at 65°C. The sequences of the disclosure may be detected using all the above conditions. For the purposes of definition, the high stringency conditions are used.
[0228] As used herein, “amplified DNA” or “amplicon” refers to the product of nucleic acid amplification of a target nucleic acid sequence that is part of a nucleic acid template. For example, to determine whether a plant resulting from a sexual cross contains this cisgenic insertion, DNA extracted from the plant tissue sample may be subjected to a nucleic acid amplification method using a DNA primer pair that includes a first primer derived from flanking sequence adjacent to, and including, the insertion site of the cisgenic DNA, and a second primer derived from the inserted cisgene to produce an amplicon that is diagnostic for the presence ofAttorney Docket No: PAT-109797-WO-SEC-1
[0229] the cisgenic insertion and the absence of backbone vector DNA. The amplicon is of a length and has a sequence that is also diagnostic for the cisgenic insertion. The amplicon may range in length from the combined length of the primer pairs plus one nucleotide base pair to any length of amplicon producible by a DNA amplification protocol, and / or the combined length of the primer pairs plus about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, or 500, 750, 1000, 1250, 1500, 1750, 2000, or more polynucleotides, plus or minus any of the increments listed above. Alternatively, primer pairs can be derived from flanking sequenceAttorney Docket No: PAT-109797-WO-SEC-1
[0230] on both sides of the inserted DNA so as to produce an amplicon that includes the entire insert nucleotide sequence of the cisgene as well as the sequence flanking the cisgenic insert. A member of a primer pair derived from the flanking sequence may be located a distance from the inserted DNA sequence, this distance can range from one nucleotide base pair up to the limits of the amplification reaction, or about 20,000 bp. The use of the term “amplicon” specifically excludes primer dimers.
[0231] TaqMan (ThermoFisher Scientific, Waltham, MA, USA.) is described as a method of detecting and quantifying the presence of a DNA sequence and is fully understood in the instructions provided by the manufacturer. Briefly, a FRET oligonucleotide probe is designed which overlaps the flanking and cisgenic insert DNA junction. The FRET probe and PCR primers (one primer in the junction and one in the flanking genomic sequence) are cycled in the presence of a thermostable polymerase and dNTPs. Hybridization of the FRET probe results in cleavage and release of the fluorescent moiety away from the quenching moiety on the FRET probe. A fluorescent signal indicates the presence of the flanking / cisgene insert sequence (and absence of vector backbone DNA) due to successful amplification and hybridization. This fluorescent signal can be quantified.
[0232] Non-limiting embodiments include
[0233] embodiments of nucleic acids and
[0234]
[0235] for i a cisgenic nucleotide
[0236]
[0237] of interest into the of a cell:
[0238] 1. An expression construct comprising at least one T-DNA having in the following order, a heterologous right border sequence, a cisgenic nucleotide sequence of interest and a heterologous left border sequence;
[0239] a) wherein the heterologous right border comprises a contiguous 5’ portion and 3’ portion; b) wherein the 3’ portion of the right border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest; and c) wherein transformation of a plant cell with said expression construct results in at least one plant cell having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming a 5’ cisgenic junction.
[0240] 2. The expression construct of embodiment 1, wherein the 3’ portion of the right border is located within the 5’ regulatory region of the cisgenic nucleotide sequence of interest.Attorney Docket No: PAT-109797-WO-SEC-1
[0241] 3. The expression construct of embodiment 1, wherein the 3’ portion of the right border is located upstream of the 5’ regulatory region of the cisgenic nucleotide sequence of interest. 4. The expression construct of embodiments 2 or 3, wherein the 5’ cisgenic junction is located from 10 kb to 100 bp upstream of the transcription start site (TSS) of the cisgenic nucleotide sequence of interest.
[0242] 5. The expression construct of embodiment 4, wherein the 5’ cisgenic junction is located from 5 kb to 1 kb upstream of the TSS of the cisgenic nucleotide sequence of interest.
[0243] 6. The expression construct of any of claims 1-3, wherein the three consecutive nucleotides is TCAorACC or CCA.
[0244] 7. The expression construct of any one of embodiments 1-3 further comprising a 3’ regulatory region of the cisgenic nucleotide sequence of interest, wherein the 3’ end of the 3’ regulatory region forms a 3’ cisgenic junction.
[0245] 8. The expression construct of any of embodiments 1-3 further comprising a second T-DNA comprising a second nucleotide sequence of interest.
[0246] 9. The expression construct of embodiment 8, wherein the second nucleotide sequence of interest is a selectable marker gene.
[0247] 10. The expression construct of embodiment 8 further comprising a spacer region between the first T-DNA and the second T-DNA.
[0248] 11. The expression construct of any of embodiments 1-10, wherein the heterologous left border comprises a contiguous 5’ portion and 3’ portion, and wherein the 5’ portion of the left border is at least “n” consecutive nucleotides that are identical to at least “n” consecutive nucleotides located within the cisgenic nucleotide sequence of interest, wherein “n” is at least 3.
[0249] 12. The expression construct of any of embodiments 1-10, wherein the 3’ portion of the right border is at least three consecutive nucleotides that are identical to at least three consecutive nucleotides located within the cisgenic nucleotide sequence of interest.
[0250] 13. An expression construct comprising:
[0251] a) a first T-DNA comprising a cisgenic nucleotide sequence of interest flanked by a heterologous right border sequence and a heterologous left border sequence, wherein the heterologous right border sequence is positioned upstream of the cisgenic nucleotide sequence of interest and the heterologous left border sequence is positioned downstream of the cisgenic nucleotide sequence of interest, wherein the heterologous right border comprises a contiguous 5’ portion and 3’Attorney Docket No: PAT-109797-WO-SEC-1
[0252] portion, wherein the 3’ portion of the right border is three, or at least three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest;
[0253] b) a second T-DNA comprising a selection marker; and
[0254] c) a spacer region between the first and the second T-DNA comprising a counterselection marker, wherein transformation of a plant cell with said expression construct results in at least one plant cell having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming a 5’ cisgenic junction.
[0255] 14. The expression construct of embodiment 13, wherein the 3’ portion of the heterologous right border sequence is located within a 5’ regulatory region of the cisgenic nucleotide sequence of interest.
[0256] 15. The expression construct of embodiment 13, wherein the three or at least three consecutive nucleotides of the 3’ portion of the heterologous right border are located at least Ikb upstream of a transcription start site of the cisgenic nucleotide sequence of interest.
[0257] 16. The expression construct of any of embodiments 13-15, wherein the heterologous left border of the first T-DNA has a contiguous 5’ portion and 3’ portion, wherein the 5’ portion of the left border is at least n consecutive nucleotides that are identical to at least n consecutive nucleotides located within the cisgenic nucleotide sequence of interest, wherein “n” is at least 3.
[0258] 17. The expression construct of any of embodiments 13-15, wherein the heterologous left border of the first T-DNA has a contiguous 5’ portion and 3’ portion, wherein the 5’ portion of the left border is at least three consecutive nucleotides that are identical to at least three consecutive nucleotides located within the cisgenic nucleotide sequence of interest.
[0259] 18. The expression construct of any of embodiments 13-17, wherein transformation of the plant cell with the expression construct results in at least one plant cell having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and further forming a 3’ cisgenic junction.
[0260] 19. The expression construct of embodiment 14 or 15, wherein the 5’ portion of the heterologous left border sequence is located within a 3’ regulatory region of the cisgenic nucleotide sequence of interest.Attorney Docket No: PAT-109797-WO-SEC-1
[0261] 20. The expression construct of embodiment 19, wherein the at least three or at least n consecutive nucleotides of the 3’ portion of the heterologous left border are located at least Ikb downstream of a transcription end site of the cisgenic nucleotide sequence of interest.
[0262] 21. The expression construct of any of embodiments 1-20, wherein the cisgenic nucleotide sequence of interest encodes a protein having a desired trait, wherein the desired trait comprises any of increased yield; increased protein or oil content, rebalanced amino acid composition, increased agronomical performance; increased disease resistance or pathogen resistance or insect resistance; increased herbicide tolerance; increased drought tolerance; increased salinity tolerance; increased heat tolerance; and modified flowering time or maturity or reproductivity.
[0263] 22. The expression construct of any of embodiments 9 or 13-21wherein the selection marker is ALS.
[0264] 23. The expression construct of embodiment 22, wherein the counterselection marker is bamase.
[0265] Example embodiments of methods for introducing a cisgenic nucleotide sequence of interest into the genome of a plant cell:
[0266] 24. A method of transforming a plant cell with a cisgenic nucleotide sequence of interest, said method comprising:
[0267] a. providing an expression construct comprising at least one T-DNA having in the following order, a right border sequence, the cisgenic nucleotide sequence of interest and a left border sequence;
[0268] i. wherein the right border comprises a contiguous 5’ portion and 3’ portion;
[0269] ii. wherein the 3 ’ portion of the right border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest; b. transforming a plant cell with the expression construct of (a); and
[0270] c. selecting for transformants having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming a 5’ cisgenic junction. 25. The method of embodiment 24, wherein the 3’ portion of the right border is located within the 5’ regulatory region of the cisgenic nucleotide sequence of interestAttorney Docket No: PAT-109797-WO-SEC-1
[0271] 26. The method of embodiment 24, wherein the 3’ portion of the right border is located upstream of the 5’ regulatory region of the cisgenic nucleotide sequence of interest.
[0272] 27. The method of embodiment 24, wherein the 5’ cisgenic junction is located from 10 kb to 100 kb upstream of the TSS of the cisgenic nucleotide sequence of interest.
[0273] 28. The method of any of embodiments 24-27, wherein the three consecutive nucleotides is TCA or CCA or ACC.
[0274] 29. The method of embodiment 24, wherein
[0275] d. the cisgenic nucleotide sequence comprises at least a portion of the 3’ regulatory region; and
[0276] e. step (c) further comprises selecting for transformants having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming both a 5’ cisgenic junction and a 3’ cisgenic junction.
[0277] 30. The method of embodiment 29, wherein the expression construct comprises a second T-DNA that comprises a second nucleotide sequence of interest.
[0278] 31. The method of embodiment 30, wherein the second nucleotide sequence of interest is a selectable marker.
[0279] 32. The method of embodiment 30 or 31, wherein the second nucleotide sequence of interest is segregable from the cisgenic nucleotide sequence of interest in a plant transformed by the method thereof.
[0280] 33. The method of any of embodiments 24-32, further comprising regenerating a plant from the selected transformants.
[0281] 34. The method of embodiment 33, further comprising crossing the regenerated plant with itself or another plant not comprising the cisgenic nucleotide sequence of interest and selecting for plants that are devoid of the second nucleotide sequence of interest.
[0282] 35. The method of embodiment 24, wherein the plant is a dicot.
[0283] 36. The method of embodiment 24, wherein the plant is a monocot.
[0284] 37. The method of embodiment 35 or 36, wherein the plant is selected from soybean, corn, cotton, rice, wheat, canola, or sunflower.
[0285] 38. The method of any of embodiments 24-37, wherein the cisgenic nucleotide sequence of interest encodes a protein having a desired trait, wherein the desired trait comprises any of increased yield; increased protein or oil content, rebalanced amino acid composition, increasedAttorney Docket No: PAT-109797-WO-SEC-1
[0286] agronomical performance; increased disease resistance or pathogen resistance or insect resistance; increased herbicide tolerance; increased drought tolerance; increased salinity tolerance; increased heat tolerance; and modified flowering time or maturity or reproductivity.
[0287] 39. A method of transforming a plant cell with a cisgenic nucleotide sequence of interest, said method comprising:
[0288] (a) providing an expression construct comprising:
[0289] (i) a first T-DNA having in the following order, a right border sequence, the cisgenic nucleotide sequence of interest and a left border sequence, wherein the right border comprises a contiguous 5’ portion and 3’ portion, wherein the 3’ portion of the right border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest;
[0290] (ii) a second T-DNA comprising a selection marker; and
[0291] (iii) a spacer region between the first and the second T-DNA comprising a counter selection marker;
[0292] (b) transforming a plant cell with the expression construct of (a); and
[0293] (c ) selecting for transformants having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming a 5’ cisgenic junction.
[0294] 40. The method of embodiment 39, wherein the 3’ portion of the right border sequence is located within a 5’ regulatory region of the cisgenic nucleotide sequence of interest.
[0295] 41. The method of embodiment 40, wherein the three consecutive nucleotides of the 3’ portion of the right border are located at least Ikb upstream of a transcription start site of the cisgenic nucleotide sequence of interest.
[0296] 42. The method of any of embodiments 39-41, wherein the left border sequence of the first T-DNA has a contiguous 5’ portion and 3’ portion, wherein the 5’ portion of the left border sequence is at least n consecutive nucleotides that are identical to at least n consecutive nucleotides located within the cisgenic nucleotide sequence of interest, wherein “n” is at least 3.
[0297] 43. The method of any of embodiments 39-42, wherein the left border sequence of the first T-DNA has a contiguous 5’ portion and 3’ portion, wherein the 5’ portion of the left border sequence is at least three consecutive nucleotides that are identical to at least three consecutive nucleotides located within the cisgenic nucleotide sequence of interest.Attorney Docket No: PAT-109797-WO-SEC-1
[0298] 44. The method of embodiment 43, wherein the 5’ portion of the left border sequence is located within a 3’ regulatory region of the cisgenic nucleotide sequence of interest.
[0299] 45. The method of any of embodiments 39-44, wherein the transformants further form a 3’ cisgenic junction when integrated into the genome of the plant cell.
[0300] 46. The method of any of embodiments 39-45, wherein the expression construct is included in a transformation vector, and wherein the transforming at (b) comprises transforming the plant cell with the transformation vector comprising the expression cassette to generate a plurality of transformants, each transformant having a distinct combination of one or more of the cisgenic nucleotide sequence of interest, the selectable marker, the counterselection marker, or a vector backbone sequence portion.
[0301] 47. The method of embodiment 46, wherein the selecting at (c) comprises selecting a subset of the plurality of transformants comprising the selection marker and the cisgenic nucleotide sequence of interest integrated into the genome of the plant cell.
[0302] 48. The method of embodiment 46, wherein the selecting at (c) comprises segregating transformants comprising the selection marker integrated into the genome of the plant cell from transformants comprising the cisgenic nucleotide sequence of interest integrated into the genome of the plant cell and devoid of the selection marker.
[0303] 49. The method of embodiment 48, wherein the segregating comprises regenerating a plant from the transformant and crossing the regenerated plant with itself or another plant not comprising the cisgenic nucleotide sequence of interest to select for plants that are devoid of the selectable marker.
[0304] 50. A plant, plant cell, or plant part made by the method of any of embodiments 24-50.
[0305] 51. A soybean plant cell made by the method of any of embodiments 24-50.
[0306] The following examples are not intended to be a detailed catalog of all the different ways in which the present disclosure may be implemented or of all the features that may be added. Persons skilled in the art will appreciate that numerous variations and additions to the various embodiments may be made without departing from the present scope of the claims. Hence, the following descriptions are intended to illustrate some particular embodiments, and not to exhaustively specify all permutations, combinations and variations thereof.Attorney Docket No: PAT-109797-WO-SEC-1
[0307] Example 1 Method of transforming a plant cell with a. cisgenic nucleotide sequence of interest Figures 3A-G depict an example method of producing a recombinant plant having a cisgenic nucleotide sequence of interest integrated into the genome at a non-native locus. The method comprises transforming a plant cell with a vector comprising an expression construct designed to enable integration of the cisgenic nucleotide sequence of interest into the genome of the host cell without introducing any undesired DNA sequence, such as without the introduction of any backbone sequence or border sequence from the vector.
[0308] As illustrated at Figure 3A, the method begins with the construction of a T-DNA vector comprising a cisgene-designated expression construct. The T-DNA vector comprises four elements as follows: (i) a first T-DNA for cisgene delivery, (ii) a second T-DNA comprising a second nucleotide sequence of interest, particularly a selection marker, for soybean plant transformation selection, (iii) an optional counterselection marker in a spacer region between the first and the second T-DNA (such that the counterselection marker is flanked on one side (e.g., the 5’ side) by the first T-DNA and on the other side (e.g., the 3’ side) by the second T-DNA, and (iv) a binary vector backbone comprising elements for providing bacterial antibiotic selection, elements for enabling amplification (such as an origin of replication), as well as elements enabling Agrobacteria-mediated plant transformation (including vir protein expressing genes). Table 1 shows an example T-DNA vector design.
[0309] In particular embodiments, the selection marker is an ALS marker (SEQ ID NO: 15) in a selection marker cassette between the left and right borders of the second T-DNA. The selection marker cassette may comprise heterologous regulatory elements operably coupled to the selection marker gene to drive expression of the ALS and enable selection of transformants. In one example, the selection marker cassette in the second T-DNA comprises the ALS marker (SEQ ID NO: 15) operably coupled to a heterologous promoter prGmEF (SEQ ID NO: 16) and a heterologous terminator tGmEPSPS (SEQ ID NO: 17).
[0310] In particular embodiments, the counterselection marker is a Bamase gene (SEQ ID NO: 11) in a counterselection expression cassette located between the two T-DNAs for counterselection of unwanted events. In one example, the counterselection marker cassette is a Bamase cassette comprises the bamase gene (SEQ ID NO: 11) operably coupled to a heterologous promoter prPCISV (SEQ ID NO: 12) and a heterologous terminator tNOS (SEQ ID NO: 14).Attorney Docket No: PAT-109797-WO-SEC-1
[0311] In particular embodiments, such as where the plant cell to be transformed is a soybean plant cell, the cisgenic nucleotide sequence of interest is a soybean cisgenic sequence encoding a resistance protein that, when expressed, confers a soybean plant or plant cell with increased disease resistance. In specific embodiments, the soybean cisgenic sequence comprises the coding sequence and associated (5’ and 3’) regulatory regions, and encodes for a resistance protein conferring resistance to Asian Soy Rust (ASR), such as the cisgenic sequence of any one of SEQ ID NOS: 7-10.
[0312] Figure 1 (panel A) illustrates a typical T-DNA that may be included in a T-DNA vector and used for integrating a gene of interest into a plant cell. The T-DNA comprises, in the following order, a right border sequence (RB), an expression cassette comprising a gene of interest operably coupled to a promoter and terminator, and a left border sequence (LB). During Agrobacterium mediated transformation, the vir protein recognizes the RB sequence of the vector and performs a site specific nick between the G and the T (of the GTCA within the right border sequence). Similarly, the vir protein recognizes the LB sequence of the vector and performs a site specific nick between the CCTG and CCA within the left border sequence. Since complete cleavage of the left border sequence occurs with low frequency during the T-DNA transfer, a portion of the vector DNA can be integrated into the genome. As illustrated, cleavage and subsequent truncation can occur at any position from the nick site until the GTT at the 5’ end of the illustrated left border sequence. To avoid inserting any undesired DNA, a novel T-DNA Figure 1 (panel B) is created comprising, in the following order, a heterologous right border sequence, a cisgenic nucleotide sequence of interest (or cisgene) comprising the coding sequence and the native 5’ regulatory region upstream of the transcription start site (TSS) that includes the native promoter, and the native 3’ regulatory region downstream of the transcription end site (TES) that includes the native terminator, and a heterologous left border sequence. To create the heterologous right border sequence, the cisgene T-DNA’ s original right border sequence is shortened by 3bp, and positioned next to the cisgene which contains at it’s 5’ terminus the identical 3bp nucleotides (TCA). In particular embodiments, the T-DNA is shortened by 3 nucleotides to remove the TCA from the border sequence, while the 5’ regulatory region of the cisgene is adjusted (extended or shortened) so that a native TCA from the 5’ regulatory region is positioned next to the modified RB. The resulting heterologous right border sequence has a 3’ portion located within, or immediately upstream of, the 5’ regulatory region of the cisgene,Attorney Docket No: PAT-109797-WO-SEC-1
[0313] ensuring the complete removal of the heterogenic border sequence following a T-DNA excision and truncation immediately adjacent to the 3bp by the combined action of the Agrobacteria VirDl and VirD2 proteins. In particular, as shown in Figure 2, transformation of the plant cell with an expression construct comprising the cisgene T-DNA results in at least one plant cell having integrated the cisgene into the genome of the plant cell and forming a 5’ ci sgenic junction that is free of undesired DNA from the vector.
[0314] To create the heterologous left border sequence, the cisgene T-DNA’s original left border is also shortened, by at least 3bp (e.g., by 4, 5, 6 or more bp, referred to generically herein as an “w-mer”) to create a minimal left border repeat sequence, and positioned next to the cisgene which contains at it’s 3’ terminus the identical / 7-mer sequence. In one particular example, (Figure 1, panel B), the T-DNA is shortened by 3bp to remove the GTT from the border sequence, while the 3’ regulatory region of the cisgene is adjusted (extended or shortened) so that a native GTT from the 3’ regulatory region is positioned next to the modified LB. In other examples, (Figure 1, panel C), the left border sequence may be shortened by 4, 5, or 6 bp. Still further examples can include the removal of any n-mer from the LB sequence. The resulting heterologous left border sequence has a 5’ portion located within or immediately downstream of the 3’ regulatory region of the cisgene which maximizes the population of clean cisgene T-DNA that is integrated into the genome of a transformed plant cell without any residual nucleotides from the left border sequence or vector sequence following a T-DNA excision (e.g., after + 12bp) and the natural T-DNA truncation. Transformation of the plant cell with an expression construct comprising the cisgene T-DNA results in at least one plant cell having integrated the cisgene into the genome of the plant cell and forming a 3’ ci sgenic junction that is free of undesired DNA.
[0315] It will be appreciated that while the above example is described with TCA as the 3bp sequence in the heterologous RB and 5’ ci sgenic junction, in still other examples, the 3bp sequence selected may be CCA. Further still, in other examples, the heterologous right border sequence may comprise more than 3 consecutive nucleotides (e.g., 4, 5, 6, or 10 nucleotides) that are identical to the more than 3 consecutive nucleotides (e.g., 4, 5, 6, or 10 nucleotides) in the cisgenic nucleotide sequence of interest.
[0316] It will be appreciated that the 5’ cisgenic junction may be located at any suitable distance upstream of the TSS, such as a distance that allows the TCA to be located without bringing in sequences from any native genes upstream of the cisgene of interest. As non-limiting examples,Attorney Docket No: PAT-109797-WO-SEC-1
[0317] the 5’ cisgenic junction may be located within less than lObp, less than 50bp, less than lOObp, between lOObp to Ikb, or between Ikb to 5kb upstream of the TSS.
[0318] It will be appreciated that the 3’ cisgenic junction may be located at any suitable distance downstream of the TES, such as a distance that allows the GTT to be located without bringing in sequences from any native genes downstream of the cisgene of interest. As non-limiting examples, the 3’ cisgenic junction may be located within less than lObp, lObp, less than 50bp, 50bp, less than lOObp, lOObp, between lOObp to Ikb, or between Ikb to 5kb downstream of the TES.
[0319] Table 2 lists example cisgenic nucleotide sequence sizes for multiple cisgenic genes of interest, including the size of the 5’ regulatory region (upstream of the TSS) that is included to provide a TCA at the heterologous RB sequence and create the 5’ cisgenic junction, as well as the size of the 3’ regulatory region (downstream of the TES) that is included to provide a GTT at the heterologous LB sequence and create the 3’ cisgenic junction.
[0320] The cisgenic genes of interest listed in Table 2 (SEQ ID NOS: 7-10) encode resistance proteins conferring resistance to Asian Soy Rust (ASR). These include proteins encoded by various resistance genes such as the Rg21 cisgene of SEQ ID NO: 7 which encodes the resistance protein RG21 (SEQ ID NO: 1 of WO2021260673), the Rg33 cisgene of SEQ ID NO: 8 which encodes theRG33 resistance protein (SEQ ID NO: 1 of WO202100878), the Rg31 cisgene of SEQ ID NO: 9 which encodes the resistance protein RG31 (SEQ ID NO: 1 of WO2024158975), and the Rg35 cisgene of SEQ II) NO: 10 which encodes the resistance protein RG35 (SEQ ID NO: 2 of WO2024158975).
[0321] Returning to Figure 3A, the first T-DNA, comprising the cisgene, comprises a cisgenic nucleotide sequence of interest flanked between a heterolgous T-DNA right border sequence (RB) and a heterologous T-DNA left border sequence (LB).
[0322] For the soy plant transformation, a second selection marker T-DNA is included in the binary T-DNA vector. In the present example, and the selection marker T-DNA comprised an expression cassette comprising an ALS gene (SEQ ID NO: 15) encoding the acetolactate synthase (ALS) double mutant (P191 A, W568L) from Nicotiana tabacum for sulfonylurea herbicide selection. This ALS T-DNA would be segregated out in T1 stage (as discussed further with reference to FIG. 3E-G (“selection”). Under some situations, if the cisgene itself can serve as a selection marker for the transgenic events, this T-DNA can be omitted in the cisgene vector design.Attorney Docket No: PAT-109797-WO-SEC-1
[0323] For counter selection, a counterselection marker cassette is included in the binary T-DNA vector in a spacer region between the first cisgene T-DNA and the second selection marker T-DNA (as discussed further with reference to FIG. 3D (“counterselection”). In the present example, a bamase cassette was located between the two T-DNAs. The 376bp promoter from Peanut Chlorotic Streak Caulimovirus (PC1SV) (SEQ ID NO: 12) was used to drive the expression of a maize codon optimized Bamase gene (SEQ ID NO: 11) from Bacillus amyloliquefaciens, which contains an iPots intron (SEQ ID NO: 13) to reduce toxicity in bacteria. Bamase is a bacterial ribonuclease (RNase) produced by Bacillus amyloliquefaciens that is toxic to the host cell when expressed without its specific inhibitor, barstar, which tightly binds to and inactivates bamase. Any T-DNA containing this cassette will not be able to generate viable plants so that it can help eliminate the undesired events resulting from insufficient T-DNA excision at the cisgene T-DNA left border and / or the selection marker T-DNA right border in the early transformation stage. This cassette can also be positioned anywhere in the vector outside of the T-DNAs to counter-select the unwanted backbone-containing events.
[0324] For the binary backbone (Table 1), the broad-host modified Japan Tobacco backbone was used for large T-DNA delivery with bacterial Spectinomycin selection marker (cSpec-03). oRK2-01 and oOriT-Ol serve as the origin of broad-host replication and origin of transfer respectively. bNRB-01-01 and bNLB-01-01 serve as the right border and left border respectively for T-DNA transfer. bNRB-04 and bBLB-05 are the extended border sequences containing overdrive sequences for higher T-DNA process efficiency.Attorney Docket No: PAT-109797-WO-SEC-1
[0325] Table 1 : Exemplary T-DNA vector design
[0326] Name Type Min Max Length Direction cTrfA-01 CDS 6270 7418 1149 Forward clncCl-Ol CDS 2015 3109 1095 Forward cKorB-01 CDS 3106 4182 1077 Forward cSpec-03 CDS 8536 9324 789 Reverse cTraJ-01 CDS 4730 5101 372 forward bNRB-04 insertion seq 4 143 140 reverse bNLB-05 insertion seq 306 435 130 reverse bNRB-01-01 insertion seq 101 125 25 reverse bNLB-01-01 insertion seq 341 365 25 reverse cos misc feature 944 1351 408 reverse xTAG-06 misc feature 144 183 40 forward xTAG-02 misc feature 258 297 40 forward I-Ceul misc feature 907 937 31 forward xSTOPS-Ol misc feature 184 195 12 forward xSTOPS-05 misc feature 245 256 12 forward ORK2-01 rep_origin 9682 10299 618 forward oOriT-Ol rep origin 4586 4697 112 reverse
[0327]
[0328] Table 2: Exemplary native regulatory sequence sizes
[0329] 5’ reg 3’ reg
[0330] Trait Total
[0331] seq. Coding seq.
[0332] SEQ RB seq LB seq size
[0333] size seq. size
[0334] ID NO. (bp)
[0335] (bp) (bp)
[0336] 7 TCA 2206 3771 GTTT 2089 8066
[0337] 8 TCA 3100 2574 GTT 1309 6983
[0338] 9 TCA 2999 15959 GTTT 2549 21897
[0339]
[0340] 19 TCA 2996 14755 GTTT 1968 19719Attorney Docket No: PAT-109797-WO-SEC-1
[0341] Example 2. Binary construct assembly and transformation
[0342] The cisgene binary constructs were constructed using standard cloning methods involving PCR, restriction enzyme digestion, ligation, and homology assembly, and were sequence-confirmed by ext generation sequencing (NGS) sequencing. Clones containing sequences matching designed sequences were propagated and transformed into Agrobacterium tumefacietis.
[0343] As illustrated in Figure 3B, during transformation, the vir proteins of the Agrobacterium machinery recognize the RB and LB sequences and create nicks. Based on the location and efficacy of the nicks, there may be a varying amount of truncation at the borders, resulting in the creation of a variety of T-DNA variants. The T-DNA variants created may comprise one or more of the selectable marker gene (SM), the countersei ection marker gene (CSM), the cisgene of interest (Cisg), as well as the vector backbone (BB) or a portion thereof. It will be appreciated that additional T-DNA variants may be created comprising truncations at the 5’ and / or 3’ ends, such as T-DNA variants comprising the cisgene cassette truncated at one or both of the 5’ and 3’ ends, the selection marker cassette truncated at one or both of the 5’ and 3’ ends, the counterselection marker truncated at one or both of the 5’ and 3’ ends, the vector backbone truncated at one or both of the 5’ and 3’ ends, or portions of any of the cassettes.
[0344] As illustrated at Figure 3C, during the Agrobacterium-mQ / A^QA transformation, the various T-DNA variants are then integrated into plant cells in various combinations. As nonlimiting examples, a first plant cell may be transformed with a T-DNA variant such that the cisgene of interest (Cisg), or a truncated version thereof, is integrated into the genome of the plant cell; a second plant cell may be transformed with a T-DNA variant such that the selection marker, or a truncated version thereof, is integrated into the genome of the plant cell; a third plant cell may be transformed with a T-DNA variant such that the counterselection marker, or a truncated version thereof, is integrated into the genome of the plant cell; a fourth plant cell may be transformed with a T-DNA variant such that the vector backbone, or a truncated version thereof, is integrated into the genome of the plant cell.Attorney Docket No: PAT-109797-WO-SEC-1
[0345] In still further examples, a fifth plant cell may be transformed with multiple T-DNA variants such that a first copy of the cisgene, or a truncated version thereof, is integrated into the genome of the plant cell at a first location while a second copy of the cisgene, or a truncated version thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of the cisgene may be integrated in the genome in other plant cells. As another example, a sixth plant cell may be transformed with multiple T-DNA variant such that a first copy of the selectable marker gene, or a truncated version thereof, is integrated into the genome of the plant cell at a first location while a second copy of the selectable marker gene, or a truncated version thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of the selectable marker gene may be integrated in the genome in other plant cells. As another example, a seventh plant cell may be transformed with multiple T-DNA variants such that a first copy of the counterselection marker, or a truncated version thereof, is integrated into the genome of the plant cell at a first location while a second copy of the counterselection marker, or a truncated version thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of the counterselection marker may be integrated in the genome in other plant cells. As another example, an eighth plant cell may be transformed with multiple T-DNA variant such that a first copy of the backbone, or a truncated version thereof, is integrated into the genome of the plant cell at a first location while a second copy of the backbone, or a truncated version thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of the backbone may be integrated in the genome in other plant cells.
[0346] As yet another example, a ninth plant cell may be transformed with multiple T-DNA variants such that a first copy of the cisgene, or a truncated version thereof, is integrated into the genome of the plant cell at a first location while a first copy of the selectable marker, or a truncated version thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of the cisgene and / or selectable marker may be integrated in the genome in other plant cells, such as two copies of the cisgene, and a single copy of the selectable marker gene; or two copies of the selectable marker gene and a single copy of the cisgene; or multiple copies of each of the cisgene and the selectable marker gene; each integrated at a distinct location of the genome of the plant cell.Attorney Docket No: PAT-109797-WO-SEC-1
[0347] As yet another example, a tenth plant cell may be transformed with multiple T-DNA variants such that a first copy of the counterselection marker (CSM), or a truncated version thereof, is integrated into the genome of the plant cell at a first location while a first copy of the selectable marker, or a truncated version thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of the CSM and / or selectable marker may be integrated in the genome in other plant cells, such as two copies of the CSM, and a single copy of the selectable marker gene; or two copies of the selectable marker gene and a single copy of the CSM; or multiple copies of each of the CSM and the selectable marker gene; each integrated at a distinct location of the genome of the plant cell.
[0348] As yet another example, an eleventh plant cell may be transformed with multiple T-DNA variants such that a first copy of the counterselection marker (CSM), or a truncated version thereof, is integrated into the genome of the plant cell at a first location while a first copy of the cisgene, or a truncated version thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of the CSM and / or cisgene may be integrated in the genome in other plant cells, such as two copies of the CSM, and a single copy of the cisgene; or two copies of the cisgene and a single copy of the CSM; or multiple copies of each of the CSM and the cisgene; each integrated at a distinct location of the genome of the plant cell.
[0349] As yet another example, a twelfth plant cell may be transformed with multiple T-DNA variants such that a first copy of any of the cisgene, CSM, selectable marker, or backbone, or a truncated version of any of these, is integrated into the genome of the plant cell at a first location while a second copy of any of the cisgene, CSM, selectable marker, or backbone, or a truncated version of any thereof, is integrated into the genome of the plant cell at a second, different location. Still more copies of any of the cisgene, CSM, selectable marker, or backbone, or a truncated version of any of these, may be integrated in the genome in other plant cells; each integrated at a distinct location of the genome of the plant cell.Attorney Docket No: PAT-109797-WO-SEC-1
[0350] As illustrated at Figure 3D, the next step of the method involves countersei ection. In particular, any transformants comprising a copy of the CSM in their genome are selected against. In an example embodiment, where the CSM comprises Barnase, transformants comprising bamase do not survive (due to the RNase activity of the barnase), thereby getting counterselected. This includes transformants comprising only bamase in their genome (in single or multiple copies), as well as transformants comprising at least one copy of bamase integrated into their genome and further comprising one or more copies of any of the cisgene, the selection marker, the vector backbone, or combinations or truncations thereof.
[0351] Next, the transformants are selected and sequence verified for the presence of the cisgenic construct. As illustrated at Figure 3E, transformants that remain after counterselection and that comprise the selection marker gene are selected using conditions based on the selection marker. Then, sequence analysis is used to identify transformants comprising at least one copy of the selection marker and at least one copy of the cisgene integrated into the genome, and further not comprising any backbone sequence integrated into the genome (cisgene positive, selection marker positive, and backbone negative). TO that met this criteria were then selfed to create T1 and T2 plants and segregants were identified that comprised only the cisgene in the genome (and comprised no selection marker sequence in the genome).
[0352] Cisgenic events were generated using the method described by Heng et al., 2024, called GiFT (genotype-independent fast transformation). The method uses germinated seeds as explants, and DNA delivery is achieved through Agrobacterium infection of wounded explants as in conventional in vitro-based methods. Fully established healthy TO transgenic events were regenerated and established in about 35 days.
[0353] Putative cisgenic events were characterized by the following steps: 1) cisgene specific assays were conducted and Cisgenic soybean lines having the desired insertion characteristics are produced from immature seed cultures following the Agrobacterium-mediated transformation protocol. Briefly, immature seeds are harvested from soybean pods cisgenic plant lines grown in the greenhouse under standard conditions. Seeds are surface sterilized, immature cotyledons are aseptically excised and cultures are maintained in flasks containing liquid media on rotary shakers under cool fluorescent light. Agrobacterium tumefaciens carrying plasmids with cisgenes of interest are used to transform the immature cotyledons of soybean plant lines. Selection of primary soybean events is achieved using an appropriate selection agent. In addition, TaqmanAttorney Docket No: PAT-109797-WO-SEC-1
[0354] analysis of the primary soybean events is performed to identify events harboring the cisgene of interest. Cisgenic events are selected and regenerated to maturity. These plants are grown under the same conditions as non-transformed or wild-type plants but in separate growth chambers. Example results of cisgenic event selection is shown in Table 3 and Figure 4.
[0355] Table 3 Cisgenic event selection
[0356] TO events generated and step-by-step selection
[0357] Cisgene Plants Single-Single, Pass Lab Pass GH Putative Good of Received Border Free phenotype rating phenotype phenotype interest rating
[0358] #1 4065 330 296 270 24
[0359] #2 2821 351 314 245 13
[0360] #3 3193 293 170 130 14
[0361] #4 1691 131 72 66 14
[0362] T1 events / pedigrees selections
[0363] Cisgene # Pedigrees # pedigree GOI Pass phenotype (# of pedigrees and high-quality cis of sown in T1 Hom / Het, rating efficiency
[0364] interest SM / JN / BB free*
[0365] #1 31 23 17 6 0.15%
[0366] #2 19 10 10 6 0.21%
[0367] #3 37 31 23 6 0.19%
[0368] #4 77 33 30 5 0.30%
[0369]
[0370] *Hom / Het = homozygous / heterozygous; SM = selectable marker, JN = junction, BB = backbone
[0371] The events were tested for efficacy against the desired phenotype and TO events with minimal acceptable efficacy were selected, followed by selection of the corresponding T1 homozygous events. The 06KG transformation line was used as wild type control. Events withAttorney Docket No: PAT-109797-WO-SEC-1
[0372] the desired phenotype are selected for maturity. This resulted in cisgenic events comprising the cisgenic nucleotide sequence of interest integrated into the genome free of any undesired or foreign sequences from the vector backbone or border.
[0373] The above examples clearly illustrate the advantages of various embodiments of the invention. Although the present invention has been described with reference to specific details of certain embodiments thereof, it is not intended that such details should be regarded as limitations upon the scope of the invention except as and to the extent that they are included in the accompanying claims.
[0374] Throughout this application, various patents, patent publications and non-patent publications are referenced. The disclosures of these patents, patent publications and non-patent publications in their entireties are incorporated by reference herein into this application in order to more fully describe the state of the art to which this invention pertains.
Claims
Attorney Docket No: PAT-109797-WO-SEC-1THAT WHICH IS CLAIMED:
1. An expression construct comprising at least one T-DNA having in the following order, a heterologous right border sequence, a cisgenic nucleotide sequence of interest and a heterologous left border sequence;a. wherein the heterologous right border comprises a contiguous 5’ portion and 3’ portion;b. wherein the 3’ portion of the right border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest;c. wherein transformation of a plant cell with said expression construct results in at least one plant cell having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming a 5’ cisgenic junction.
2. The expression construct of claim 1, wherein the 3’ portion of the right border is located within the 5’ regulatory region of the cisgenic nucleotide sequence of interest.
3. The expression construct of claim 1, wherein the 3’ portion of the right border is located upstream of the 5’ regulatory region of the cisgenic nucleotide sequence of interest.
4. The expression construct of claims 2 or 3, wherein the 5’ cisgenic junction is located from 10 kb to 100 bp upstream of the transcription start site (TSS) of the cisgenic nucleotide sequence of interest.
5. The expression construct of claim 4, wherein the 5’ cisgenic junction is located from 5 kb to 1 kb upstream of the TSS of the cisgenic nucleotide sequence of interest.
6. The expression construct of any of claims 1-3, wherein the three consecutive nucleotides is TCA or ACC.
7. The expression construct of any of claims 1-3 further comprising a 3’ regulatory region of the cisgenic nucleotide sequence of interest, wherein the 3’ end of the 3’ regulatory region forms a 3’ cisgenic junction.
8. The expression construct of any of claims 1-3 further comprising a second T-DNA comprising a second nucleotide sequence of interest.
9. The expression construct of claim 8, wherein the second nucleotide sequence of interest is a selectable marker gene.Attorney Docket No: PAT-109797-WO-SEC-110. The expression construct of claim 8 further comprising a spacer region between the first T-DNA and the second T-DNA.
11. A plant or a plant part thereof comprising a first region comprising genomic DNA of the plant and a second region comprising a cisgenic nucleotide sequence of interest, wherein the first region and second region form a 5’ cisgenic junction.
12. The plant or plant part of claim 11, wherein the cisgenic nucleotide sequence of interest comprises a 5’ regulatory region of the cisgene.
13. The plant or plant part of claim 11 or 12, wherein the 5’ cisgenic junction is located from 10 kb to 100 bp upstream of the TSS of the cisgenic nucleotide sequence of interest.
14. The plant or plant part of claim 13, wherein the 5’ cisgenic junction is located from 5 kb to 1 kb upstream of the TSS of the cisgenic nucleotide sequence of interest.
15. The plant or plant part of claim 11 or 12, wherein the cisgenic nucleotide sequence of interest further comprises a 3’ regulatory region of the cisgenic nucleotide sequence of interest, wherein the 3’ end of the 3’ regulatory region forms a 3’ cisgenic junction with genomic DNA of the plant.
16. The plant or plant part of claims 11 or 12, wherein the plant is a dicot.
17. The plant or plant part of claims 11 or 12, wherein the plant is a monocot.
18. The plant or plant part of claim 11 or 12, wherein the plant is selected from soybean, com, cotton, rice, wheat, canola, or sunflower.
19. A method of transforming a plant cell with a cisgenic nucleotide sequence of interest, said method comprising:a. providing an expression construct comprising at least one T-DNA having in the following order, a right border sequence, the cisgenic nucleotide sequence of interest and a left border sequence;i. wherein the right border comprises a contiguous 5’ portion and 3’ portion; ii. wherein the 3 ’ portion of the right border is three consecutive nucleotides that are identical to three consecutive nucleotides located within the cisgenic nucleotide sequence of interest;b. transforming a plant cell with the expression construct of (a); andc. selecting for transformants having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming a 5’ cisgenic junction.Attorney Docket No: PAT-109797-WO-SEC-120. The method of claim 19, wherein the 3’ portion of the right border is located within the 5’ regulatory region of the cisgenic nucleotide sequence of interest21. The method of claim 19, wherein the 3’ portion of the right border is located upstream of the 5’ regulatory region of the cisgenic nucleotide sequence of interest.
22. The method of claim 20, wherein the 5’ cisgenic junction is located from 10 kb to 100 kb upstream of the TSS of the cisgenic nucleotide sequence of interest.
23. The method of any of claims 19-22, wherein the three consecutive nucleotides is TCA or ACC.
24. The method of claim 19, whereind. the cisgenic nucleotide sequence comprises at least a portion of the 3’ regulatory region; ande. step (e) further comprises selecting for transformants having integrated the cisgenic nucleotide sequence of interest into the genome of the plant cell and forming both a 5’ cisgenic junction and a 3’ cisgenic junction.
25. The method of claim 19, wherein the expression construct comprises a second T-DNA that comprises a second nucleotide sequence of interest.
26. The method of claim 25, wherein the second nucleotide sequence of interest is a selectable marker.
27. The method of claim 25 or 26, wherein the second nucleotide sequence of interest is segregable from the cisgenic nucleotide sequence of interest in a plant transformed by the method thereof.
28. The method of any of claims 19-27, further comprising regenerating a plant from the selected transformants.
29. The method of claim 28, further comprising crossing the renegerated plant with itself or another plant not comprising the cisgenic nucleotide sequence of interest and selecting for plants that are devoid of the second nucleotide sequence of interest.
30. The method of claim 19, wherein the plant is a dicot.
31. The method of claim 19, wherein the plant is a monocot.
32. The method of claim 30 or 31, wherein the plant is selected from soybean, corn, cotton, rice, wheat, canola, or sunflower.
33. A plant or a part thereof regenerated from the method of any of claims 19-27.
